Title page, Vol 23 - Public Healthsph.lsuhsc.edu › wp-content › uploads › 2016 › 08 › Vol23.pdfVolume 23 Cancer in Louisiana, 2001-2005 editors Patricia A. Andrews, MPH Meichin

2001-2005

CanCer inLouisiana

L T R

Louisiana Tumor Registry

Cancer in LouisianaVolume 23

Cancer in Louisiana

Volume 23

Cancer in Louisiana, 2001-2005

editors

Patricia A. Andrews, MPH Meichin Hsieh, MSPH Brent Mumphrey, BS

Lisa A. Pareti, BS, RHIT Beth A. Schmidt, MSPH

Mary Namiak, MPH Edward S. Peters, DMD, SM, ScD

Xiaocheng Wu, MD, MPH Vivien W. Chen, PhD

Louisiana Tumor Registry Epidemiology Program, School of Public Health

Louisiana State University Health Sciences Center–New Orleans

http://publichealth.lsuhsc.edu/tumorregistry [email protected]

New Orleans 2008

ii

The work on this monograph was supported in part by: The LSU Health Sciences Center in New Orleans,

SEER Contract #NO1-PC-54402 from the National Cancer Institute, and Cooperative Agreements 5U58DP000769, U75/CCU618724, and U55/CCU621886

from the Centers for Disease Control and Prevention (CDC).

The contents of the monograph are solely the responsibility of the authors.

Suggested Citation: Andrews PA, Hsieh M, Mumphrey B, Pareti LA, Schmidt BA, Namiak M, Peters ES, Wu X, Chen VW (eds).Cancer in Louisiana, 2001-2005. New Orleans: Louisiana Tumor Registry, 2008. (Cancer in Louisiana; Vol. 23.)

Contents Title Citation Contents Summary Introduction Presentation of the Data Regions of the Louisiana Tumor Registry Acknowledgments Web Addresses for Cancer-Related Organizations Figures: Special Topics Figure 1. All Cancers Combined Figure 2. Lung Cancer Figure 3. Colorectal Cancer Figure 4. Female Breast Cancer Figure 5. Prostate Cancer Figure 6. Cervical Cancer Figure 7. Tobacco-Related Cancers Incidence Tables Table A1 Average Annual Number of New Cancer Cases, 2001–2005, Louisiana Table A2 Percent Distribution of Cancer Cases, 2001–2005, Louisiana Table B Average Annual Cancer Incidence Rates, 2001–2005: Louisiana Tables C1-C4: Ten Most Commonly Diagnosed Cancers, 2001-2005, by Louisiana Parish Table C1 White males Table C2 White females Table C3 Black males Table C4 Black females Tables D1–D5 Ten Most Commonly Diagnosed Cancers: U.S., Louisiana, and Louisiana Tumor

Registry Regions Table D1 White males Table D2 White females

Table D3 Black males Table D4 Black females Tables E1–E4 Ten Most Commonly Diagnosed: U.S., Louisiana, and Louisiana Office of Public

Health Regions Table E1 White males Table E2 White females Table E3 Black males Table E4 Black females

Table F Average Annual Incidence Rates for Selected Cancers: U.S., Louisiana, and Industrial Corridor

2

Cancer Death Tables Table G1 Average Annual Number of Cancer Deaths, 2001–2005: Louisiana Table G2 Percent Distribution of Cancer Deaths, 2001–2005: Louisiana Table H Average Annual Death Rates, 2001–2005: Louisiana Table I Average Annual Death Rates for Selected Cancers: U.S., Louisiana, and

Industrial Corridor Tables J1–J4 Ten Leading Causes of Cancer Deaths: U.S., Louisiana, and Louisiana Tumor

Registry Regions Table J1 White males

Table J2 White females Table J3 Black males

Table J4 Black females Tables K1–K4 Ten Leading Causes of Cancer Deaths: U.S., Louisiana, and Louisiana Office of

Public Health Regions Table K1 White males

Table K2 White females Table K3 Black males

Table K4 Black females Appendices Appendix 1 Cancer in Louisiana Monograph Series Appendix 2 Louisiana Tumor Registry Addresses and Phone Numbers Appendix 3 SEER Primary Site Recodes for Incidence (ICD-O-3) Appendix 4 SEER Site Recodes for Mortality (ICD-10) Appendix 5 Louisiana Office of Public Health Regions Appendix 6 Louisiana Population Counts, 2001-2005 Appendix 7 References

Summary Cancer in Louisiana, 2001−2005

Incidence 1. During the five-year period 2001–2005, an average of 21,047 invasive cancer cases per year were diagnosed among Louisiana residents (Table A1). 2. For all Louisianians combined, the most frequently diagnosed cancers were lung (16%), prostate (16%), breast (14%), colon & rectum (12%), and urinary bladder (4%) (Table A2). 3. The five most common invasive cancers by race/sex group were

-- White men: prostate (27% of all cases diagnosed among white males), lung (18%), colon & rectum (11%), urinary bladder cancers (7%), and non-Hodgkin lymphoma (4%)

-- African-American males: lung (33%), prostate (13%), colon & rectum (10%), pancreas (5%), and liver (4%) cancers men: prostate (33%), lung (19%), colon & rectum (11%), kidney (4%), and oral cavity (3%) cancers

-- White women: breast (29%), lung (16%), colon & rectum cancers (12%), non-Hodgkin lymphoma (5%), and uterine cancer (uterus and corpus) (4%)

-- African-American women: breast (31%), colon & rectum (14%), lung (12%), uterus (5%), and cervix (4%) (Table A2)

4. Although the incidence rates for cancers of all sites combined among white men and African-American men in Louisiana were significantly higher than those for their national counterparts, the rate for African-American women in Louisiana was similar to national levels and that for white women was significantly lower (Table F). This pattern persists even if lung cancer is excluded. 5. Lung cancer rates have been historically high in Louisiana. For white men the incidence rates were significantly higher than in the U.S. in every LTR region; for African-American men, they were higher in all but one region. Statewide, white women’s lung cancer rate was significant higher in Louisiana than the U.S., but that for African-American women was significantly low (Table F). 6. Cancers for which Louisiana had significantly higher rates than the U.S. include: -- White men: oral cavity & pharynx, colon & rectum, liver, larynx, lung, prostate, kidney cancers;

Hodgkin lymphoma -- African-American men: oral cavity & pharynx, stomach, colon & rectum, pancreas, larynx, and

lung cancers; myeloma -- White women: colon & rectum, larynx, lung, and kidney cancers -- African-American women: stomach, breast, and cervical cancers (Table F) 6, Louisiana incidence rates were significantly lower than the U.S. rates for -- White men: stomach cancer and melanoma of the skin -- White women: stomach, breast, uterine, ovarian, and thyroid cancers and melanoma of the skin. -- African-American women: lung and uterine cancers (Table F) 7. In the Industrial Corridor, white men had significantly lower incidence rates for all cancers combined than their statewide counterparts. Rates for white women were lower and those for African Americans were higher than in Louisiana, but these differences were not statistically significant. The Industrial Corridor includes Ascension, East Baton Rouge, Iberville, St. James, St. John the Baptist, St. Charles, and West Baton Rouge parishes. (Table F)

Cancer Deaths

1. An average of 9,435 deaths per year were attributed to cancer (Table G1). Only heart disease causes more deaths (an average of 11,212 per year in Louisiana in 2001-2005; data not shown). 2. The most common causes of death from cancer in Louisiana were: -- White males: lung (35% of all cancer deaths among white men), colon & rectum (10%), prostate

(8%), and pancreatic cancers (5%), and non-Hodgkin lymphoma (4%) -- African-American males: lung (33%), prostate (13%), colon & rectum (10%), pancreas (5%), and liver (4%) cancers -- White females: lung (28%), breast (15%), colon & rectum (10%), pancreas (6%), and ovarian (5%) cancers.

-- African-American females: breast (21%), lung (20%), colon & rectum (12%), pancreas (7%), and ovarian (4%) cancers (Table G2)

3. Statewide, each of the four major race/sex groups had significantly higher death rates for all sites combined than their national counterparts (Table I). This is true even if lung cancer is excluded from the totals (data not shown). 4. Death rates in the Industrial Corridor, all cancers combined, were lower than those for Louisiana for the four major race/sex groups. These differences were statistically significant for men and for white women. (Table I) Note: All incidence and death rates in this volume are average annual rates for the five-year period. Rates are age adjusted to the U.S. 2000 standard and should not be compared with rates that are adjusted to the 1970 population.

Introduction

The Louisiana Tumor Registry is pleased to present Volume 23 of its annual Cancer in Louisiana monograph series, documenting cancer incidence and mortality in Louisiana from 2001 through 2005. This volume includes, for the first time, comments on several important types of cancer (Figures 1-6) as well as incidence and mortality rates for the Louisiana Office of Public Health regions. A list of earlier publications in this series can be found in Appendix 1.

Purpose of the Registry

The Louisiana Tumor Registry (LTR) was created by the state legislature to collect, analyze and disseminate information on cancer in Louisiana. Cancer is a reportable disease in all states of the U.S. Using the data they compile, statewide population-based registries are able to calculate cancer incidence statistics by age, race, sex, and geographic region. With the resulting statistics, including trends over time, data-driven cancer prevention and control programs can be implemented to reduce cancer morbidity and mortality. Registry data provide the foundation for studies evaluating clinical therapies, health care planning, screening and early detection programs, and other cancer prevention and control initia-tives. Using registry information, we can work to lessen the burden of cancer in our state.

Historical Background of the LTR

Cancer registration in Louisiana began in 1947 in the Charity Hospital Tumor Registry in New Orleans and was limited to patients in that facility. In 1974, as part of its Surveillance, Epidemiology and End Results (SEER) Program, the National Cancer Institute (NCI) provided funds for a population-based cancer incidence and survival registry. Data from the Louisiana Tumor Registry, which then encompassed only Jefferson, Orleans, and St. Bernard parishes, were included in the 1974−1977 SEER national incidence rates. In 1979, the LTR was transferred to Louisiana’s Office of Public Health (OPH). The catchment area for the LTR was expanded in 1983 to include 35 parishes of South Louisiana (Regions 1–5). In 1988, when the 29 parishes of North Louisiana

(Regions 6–8) were added, statewide coverage was achieved. Vivien W. Chen, Ph.D., became director of the registry in 1991. Since 1994, the Centers for Disease Control and Prevention (CDC) has provided funds for most states, including Louisiana, to participate in the National Program of Cancer Registries. In 1995, the registry was transferred from the OPH to the LSU Board of Supervisors. Since then, the LSU Health Sciences Center in New Orleans has been responsible for the cancer registry program and has provided state funds for its work. In 2001, after a competitive application process, the Louisiana Tumor Registry was selected to join the SEER Program of the National Cancer Institute as an expansion registry on a provisional basis. Four years later, it became a full member of SEER. As such, the LTR again receives additional funds from the NCI. Oversight of the registry is exercised by the Louisiana Cancer and Lung Trust Fund Board, whose members represent various health institutions throughout the state and are appointed by the governor (see Acknowledgements).

Operations of the Registry

The operations of the registry are mandated by public law, R.S. 40:1299.80 et seq., which directs all medical facilities and health care providers to report all cancer cases to the registry. The same rules require strict confidentiality of all data.

Central Office and Regional Registries

The Louisiana Tumor Registry is composed of a central office and eight regional registries that collect and process cancer incidence data from geographic areas based on Louisiana’s historic Office of Public Health districts. (See the “Regions of the Louisiana Tumor Registry” page and Appendix 2.) Collection of Cancer Incidence Data

Each regional registry is responsible for the complete ascertainment of data on cancer diagnoses and treatment in its region within six months of diagnosis. About one fourth of all hospitals in Louisiana maintain their own cancer registries, and the regional registries are responsible for abstracting cases from the remaining hospitals and other facilities such as freestanding pathology labs, treatment centers, outpatient surgical facilities, and physician offices. Regional registries monitor the facilities in their area for completeness of case ascertainment, as well as editing case abstracts, consolidating multiple reports on the same case, and assisting in training new hospital registry employees. The central office coordinates regional offices to ensure the quality, completeness and timeliness of reporting. In addition, its research staff prepares publications and participates in research activities. Unregistered cancer diagnoses identified among Louisiana residents through death certificates are traced back to hospitals, other facilities or physician offices to be abstracted. If the original diagnostic information cannot be located, the case is considered a “death-certificate-only” case, and the date of death is recorded as the diagnosis date. Interstate exchange of data with other states began in 1997 in order to ensure a higher level of case ascertainment and data completeness. This permits the LTR to obtain cancer data on residents of Louisiana who have traveled out of state for cancer diagnosis and/or treatment. Louisiana has such agreements with 19 states, including all neighboring states. Strict protocols on patient confidentiality are followed.

Reportable Diagnoses

The Louisiana Tumor Registry complies with national standards in requiring that all in situ and invasive neoplasms (cancers with behavior codes 2 or 3 in the ICD-O-21or ICD-O-32) be reported. The exceptions are intraepithelial or in situ carcinomas of the cervix, intraepithelial carcinoma of the prostate, and basal cell and squamous cell carcinomas of the skin. Pilocytic astrocytomas are classified as benign by the World Health Organization but are considered malignant in North America. Beginning in 2004, benign and borderline tumors (behavior codes of 0 or 1) of the brain and central nervous system are also reportable. Data Quality

Quality assurance procedures in the regional registries and central office minimize abstracting and coding errors and evaluate the completeness of case ascertainment. To enhance the quality of incidence data across the United States, the North American Association of Central Cancer Registries (NAACCR) sets standards for quality, timeliness, and completeness. Data from U.S. registries that meet those standards are used in calculating the “U.S. Combined Cancer Incidence Rates,” which are reported in NAACCR’s annual publication, Cancer in North America.3 Louisiana Tumor Registry data have qualified for inclusion every year since the inception of the certification process in 1997 and have been certified at the gold level for the past eleven years, LTR data are also included in other cancer surveillance publications that accept only high-quality data: Cancer Incidence in Five Continents,4 published by the World Health Organization’s International Association for Research on Cancer; United States Cancer Statistics,5 published by the CDC and the NCI; and SEER Cancer Statistics Review,6 published by the SEER Program.

Confidentiality of Data

Confidentiality is the highest priority in registry operations. Louisiana law mandates strict confidentiality of data about cancers and health care providers and protects participating facilities and physicians from any liability that may arise from reporting to the cancer registry program.

LTR personnel sign an “Agreement to Maintain Confidentiality of Data” and are subject to penalty if they disclose confidential information. LTR data are published in aggregate form only. Data released in public presentations or publications are not intended to correspond to individual cases.

Presentation of Data

Volume 23 of Cancer in Louisiana presents cancer incidence and mortality information about residents of Louisiana diagnosed with cancer between January 1, 2001, and December 31, 2005. Statistics on incidence are found in Tables A–F, and Tables G–K contain data on mortality. Incidence or mortality rates are not calculated for cells smaller than sixteen, as rates based on small counts tend to be unstable.

Data Use Standards

Incidence

The LTR follows standard protocols in computing and publishing cancer incidence data so that Louisiana data can be compared with those from other cancer surveillance publications. These conventions include:

Only primary cancers are included in the LTR database used for calculating incidence counts or rates. Recurrent or metastatic cases are excluded.

Rules from the SEER Program determine whether multiple primary cancers for a given patient are considered one case or more than one.

For preparing statistics, anatomic subsites are combined according to code group-ings of the SEER Program of the National Cancer Institute (Appendix 3).

With the exception of bladder cancer, only invasive neoplasms are included in the tables. For cancers of the bladder, both in situ and invasive cases are included. In situ carcinomas of the breast are listed separately from the invasive cancers and are excluded from the “all sites” total.

Neoplasms of the lymphatic, hemato-poietic, and reticuloendothelial systems (e.g., lymphomas and leukemias), as well as mesothelioma and Kaposi sarcoma, are

grouped by their histologies and not by the anatomical sites where they occur.

Cancer Deaths

Information on residents of Louisiana who died with cancer as the underlying cause of death was compiled by the National Center for Health Statistics, using mortality data from the Louisiana Office of Public Health and its counterparts in other states. Louisiana residents who died out of state are included in Louisiana statistics.

The SEER Program has grouped the anatomical site codes from the International Classification of Diseases, 10th Revision7 (Appendix 4). These groupings are used by cancer surveillance agencies for calculating mortality statistics.

Race

Race for cancer cases is based primarily on information contained in a patient’s medical record, supplemented by information on death certificates. The LTR has made great efforts to resolve discrepancies.

Louisiana cancer incidence and mortality data in this volume include the racial categories of white, black, and all races combined. Other groups were not analyzed separately because of their small numbers. Less than one percent of 2001–2005 cases were of unknown race. Cases with unknown race were included in the calculations of rates for “all races” but not in the race-specific computations.

Population Estimates

Five-year population estimates by race, sex and age for Louisiana and the U.S. were obtained from the National Cancer Institute and are based on the U.S. Census Bureau’s estimates of the populations for 2001−2005 (Appendix 6). See also: “Cal-culating 2005 Statistics,” below.

Age Adjustment

Age adjustment allows meaningful comparisons of cancer risk in different populations by controlling for differences in the age distributions of those populations. This is important because

cancer is diagnosed more frequently among the elderly. Age-adjusted rates are the weighted average of the age-specific rates, where the weights represent the age distribution of a standard population.

Rates in this monograph are age adjusted to the 2000 U.S. standard population. Rates in earlier publications (with data predating 1999), however, were age adjusted to the 1970 U.S. standard population. Because the U.S. populace was older in 2000 than in 1970, the new standard will cause most rates to appear to rise markedly. Thus, incidence and mortality rates in Volumes 1-16 of this series should not be compared with those in subsequent volumes.

More information on age adjustment may be found at the NAACCR website.8

Calculating 2005 Rates

Hurricanes Katrina and Rita brought unique challenges to researchers calculating incidence and mortality statistics in Louisiana and the Gulf South. Information on some newly diagnosed cases was destroyed by flooding and could not be re-created. In addition, the exodus of hundreds of thousands of residents meant that population data, required for calculating rates, were also difficult to estimate in those areas.

States that sheltered Louisiana residents submitted case reports to Louisiana, and the LTR contacted pediatric hospitals throughout the country to obtain information on Louisiana children treated there.

Because of the uncertainties related to identifying all new cases and locating complete records, as well as estimating the 2005 population after Hurricane Katina, , the SEER Program of the NCI developed a Louisiana-specific algorithm.

This calculation is based on the assumption that incidence rates for the first half of a year are about the same as rates for the second half of the year. Therefore, for calculating rates, the U.S. Census Bureau’s population estimate for 2005 was divided by two to create the denominator, and the case counts for the first half of the year were used as the numerator. Case counts in this volume, however, are based on actual counts for the entire

year.

The National Center for Health Statistics forwarded to Louisiana the death certificate information for Louisiana residents who died in other states. SEER statisticians made an adjustment for displaced populations for 2005 mortality rates in Gulf states, and the resultant mortality rates presented here are in line with those for the preceding years. Calculations of mortality rates are based on 12 months’ deaths and the adjusted population.

For more details, see http://seer.cancer. gov/popdata/methods.html.

Comparison Groups

Incidence

Estimates of the average annual age-adjusted incidence rates for the U.S. were calculated by the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. Data from the SEER Program are recognized for their high quality, and SEER estimates have been traditionally cited as national rates.

The SEER Program estimates in this volume are based on data representing about 26% of the U.S. population. These come from nine state registries (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico and Utah), three metropolitan areas (Atlanta, Detroit, and Seattle/Puget Sound), a group of ten rural counties in Georgia, and the combined American Indian/Alaska Natives of Arizona and Alaska.

Mortality

Mortality statistics for the United States are based on data from the National Center for Health Statistics, to which all states submit death certificate information.

Cautions in Interpretation In comparing rates among geographic areas it is important to keep in mind that a variety of factors, in addition to true differences in the risk of developing or dying from cancer, can contribute to variations in cancer rates. Geographic

differences should, therefore, be interpreted with caution and should be used to generate, not test, hypotheses.

Rates based on small numbers may be unstable. For this reason, federal agencies and some states have guidelines for minimum counts. This issue of Cancer in Louisiana publishes rates based on

sixteen or more cases for a five-year period, in conformity with the standards of the “Annual Report to the Nation,” published by the American Cancer Society, the North American Association of Central Cancer Registries, the CDC, and other surveillance agencies.

Abbreviations Used in This Volume

ICD-O-2 International Classification of Diseases for Oncology, 2nd edition

ICD-O-3 International Classification of Diseases for Oncology, 3rd edition

LTR Louisiana Tumor Registry

NCI National Cancer Institute

NAACCR North American Association of Central Cancer Registries

OPH Louisiana Office of Public Health

-- Not applicable; rate is not calculated for case counts lower than six

SEER Surveillance, Epidemiology and End Results Program of the National Cancer Institute

Regions of the Louisiana Tumor Registry Regional registry Beginning date Average annual Parishes covered of the Registry Population 20012005

New Orleans 1974 982,586 Jefferson, Orleans, St. Bernard (Region 1) Baton Rouge 1983 846,910 Ascension, Assumption, East Baton (Region 2) Rouge, East Feliciana, Iberville,

Livingston, Pointe Coupée, St. Helena, Tangipahoa, West Baton Rouge, West Feliciana

Southeast Louisiana 1983 592,099 Lafourche, Plaquemines, St. Charles, (Region 3) St. James, St. John, St. Tammany,

Terrebonne, Washington Acadiana 1983 606,890 Acadia, Evangeline, Iberia, Lafayette, (Region 4) St. Landry, St. Martin, St. Mary, Vermilion Southwest Louisiana 1983 283,481 Allen, Beauregard, Calcasieu, (Region 5) Cameron, Jefferson Davis Central Louisiana 1988 298,775 Avoyelles, Catahoula, Concordia, (Region 6) Grant, La Salle, Rapides, Vernon, Winn Northwest Louisiana 1988 523,057 Bienville, Bossier, Caddo, Claiborne, (Region 7) De Soto, Natchitoches, Red River, Sabine,

Webster Northeast Louisiana 1988 349,789 Caldwell, East Carroll, Franklin, (Region 8) Jackson, Lincoln, Madison, Morehouse,

Ouachita, Richland, Tensas, Union, West Carroll

Entire state 1988 4,483,586 Source: U.S. Bureau of Census and National Cancer Institute, April 2008.

Acknowledgements

As with all reports produced by the LTR, much appreciation goes to those whose dedication and hard work provide the foundation for these monographs. These include: Louisiana Tumor Registry Regional Directors Anna G. Moore, CTR, Regions 1 & 3 Angela Crossgrow, CTR, Regions 1 & 3 Nicole Magee, CTR, Region 2 Lea G. Guidry, RHIA, CTR, Region 4 Ellyn C. Baker, RHIT, CTR, Region 5 Nadine S. Johnston, RHIA, CTR, Regions 6 & 8 Tracey McDuffie, CTR, Region 6 Amber Mandino, RHIA, CTR, Region 7 Sara Beth Copes, RHIA, CTR, Region 7 Melanie Byargeon, RHIA, CTR, Region 8 Martha K. Love, CTR, Region 8 For work contributing to this monograph: Registrars and staffs of the central and regional

LTR offices Betty Gonzales, MBA Registrars and staffs of all Louisiana hospital

cancer programs Physicians and staffs in pathology laboratories

and treatment centers Hospice programs Coroners’ offices Office of Public Health Louisiana Department of Health and Hospitals Assistant Secretary for OPH M. Rony Francois, MD, MSPH, PhD Deputy Secretary Sybil Richard, Esq., R.Ph, MHA State Registrar and Director, Vital Records and Health Statistics Darlene W. Smith Louisiana Center for Health Statistics Joan Borstell, MS

Louisiana Cancer and Lung Trust Fund Board Representatives Acadiana Medical Research Foundation John M. Rainey, MD American Cancer Society Charles L. Brown, Jr., MD American Heart Association Jack P. Strong, MD American Lung Association Joseph A. Lasky, MD, FCCP Leukemia Society of America Carl G. Kardinal, MD Louisiana State Medical Society M. Patrick Stagg, MD LSU Health Sciences Center–New Orleans Augusto Ochoa, MD LSU Health Sciences Center–Shreveport Jonathan Glass, MD Mary Bird Perkins Cancer Center Todd D. Stevens, MBA. Ochsner Medical Foundation John T. Cole, MD Tulane University School of Medicine Alan M. Miller, PhD, MD Xavier University Wayne Harris, PhD LCLTFB Administrator: Ana Ruiz

Web Addresses for Cancer-Related Organizations

American Cancer Society: http://www.cancer.org

Behavioral Risk Factor Surveillance System: www.cdc.gov/brfss

Centers for Disease Control and Prevention: http://www.cdc.gov/

Louisiana Breast and Cervical Screening Program: http://labchp.lsuhsc.edu/Services_2.htm

Louisiana Cancer and Lung Trust Fund Board: http://www.lcltfb.org

Louisiana Cancer Control Partnership: http://www.lcltfb.org/CC-Plan/default.htm

Louisiana Cancer Registrars’ Association: http://www.lcra-usa.org

Louisiana Office of Public Health: http://www.oph.dhh.state.la.us

National Cancer Institute: http://cancer.gov

State Cancer Profiles: http://statecancerprofiles.cancer.gov

Tobacco-Free Louisiana: http://www.tobaccofreelouisiana.org or http://www.mytfl.org

Figures

Figure 1. All Cancers Combined, 2001-2005

Average Annual Rates per 100,000 Incidence Mortality

# U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. * The Louisiana rate differs significantly from the U.S. rate (p < 0.05). An average of about 21,000 cases of invasive cancer were diagnosed each year, 2001-2005, in Louisiana. If all race/sex groups are combined, cancers of the lung, prostate, breast, colon & rectum, and bladder (in that order) have the highest incidence rates in Louisiana. In the U.S., however, the following is the order of highest rates: prostate, breast, lung, colon & rectum, and bladder. Cancer caused an average of almost 9,500 deaths per year in Louisiana. Only heart disease causes more deaths than cancer, both in Louisiana and nationally. The major causes of cancer deaths in both Louisiana and the U.S. were malignancies of the lung, colon & rectum, breast, pancreas, and prostate. Cancer mortality rates have been declining in Louisiana and the U.S. since the early 1990s. This decline is more rapid among men than among women.

How Does Louisiana Rank Compare with Other States? 10 All Cancers Combined, 2004

White Men White Women Black Men Black Females

Incidence 4 24 3 14

Mortality 8 15 1 10

0

100

200

300

400

500

600

700

800

whitemen*

blackmen*

whitewomen*

blackwomen

Louisiana U.S.#

0

100

200

300

400

500

600

700

800

whitemen*

blackmen*

whitewomen*

blackwomen*

Louisiana U.S.

Figure 2. Lung Cancer, 2001-2005


. # U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. * The Louisiana rate differs significantly from the U.S. rate (p < 0.05). Lung cancer accounts for almost one out of six cancer new diagnoses and one out of three cancer deaths each year in Louisiana and the U.S. Lung cancer incidence and death rates are significantly higher in Louisiana than in the U.S. for men and for white women. Incidence rates for Louisiana black women, however, are significantly low. Among men in both Louisiana and the U.S, lung cancer incidence and mortality rates have been trending downward for over ten years, but for women they continue to rise gradually. This is true both in Louisiana and nationally. Among black men, Louisiana ranked 4th in the nation for incidence of lung cancer in 2004; the ranks for other Louisiana groups are: white men, 5th; white women, 11th; and black women, 23rd.10

Risk factors for lung chacer: The American Cancer Society states that cigarette smoking is the most important risk factor and that the risk increases with the quantity and duration of cigarette use. Other risk factors include exposures to secondhand smoke, radon, asbestos (particularly among smokers), certain metals and organic chemicals, radiation, and air pollution; a history of tuberculosis; and family history of lung cancer.9

0

20

40

60

80

100

120

140

160

white men* black men* whitewomen*

blackwomen*

Louisiana U.S. #

0

20

40

60

80

100

120

140

160


blackwomen*

Louisiana U.S.

Figure 3. Colorectal Cancer, 2001-2005

Average Annual Rates per 100,000 Incidence Mortality # U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. * The Louisiana rate differs significantly from the U.S. rate (p < 0.05). Among men, colorectal cancer is the third most commonly diagnosed cancer, and among white women it ranks third. For Louisiana black women, however, colorectal cancer has become the second-most commonly diagnosed cancer. For all race-sex groups, Louisiana incidence and mortality rates exceed national rates. For mortality, colorectal cancer generally ranks third for all four race-sex groups. The one exception is Louisiana white men, for whom the colorectal cancer mortality rate slightly exceeds that for prostate cancer. Death rates from colorectal cancer have been trending downward among all four race-sex groups in the U.S., but among Louisiana men they remain level. Louisiana residents diagnosed with colorectal cancer are slightly more likely to be diagnosed with disease that has spread beyond the colon or rectum than are their counterparts nationally. Increased use of screening tests such as endoscopy (which can remove pre-cancerous polyps) and fecal occult blood tests will help reduce both the number and the severity of new cases. Risk factors: The risk of colorectal cancer increases with age. In addition, according to the American Cancer Society, the following modifiable factors can increase the likelihood of this diagnosis: obesity, physical inactivity, smoking, heavy alcohol consumption, a diet high in red and/or processed meats, and low consumption levels of fruits and vegetables. A family history of colon cancer and/or polyps can also increase the risk of colorectal cancer.9

0

10

20

30

40

50

60

70

80

90


blackwomen

Louisiana U.S.#

0

10

20

30

40

50

60

70

80

90

white men* blackmen*

whitewomen

blackwomen

Louisiana U.S.

Figure 4. Female Breast Cancer, 2001-2005


0

20

40

60

80

100

120

140

160

white women* black women* Louisiana U.S.#

# U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. * The Louisiana rate differs significantly from the U.S. rate (p < 0.05).

Breast cancer is by far the most frequently diagnosed cancer among women, both in Louisiana and the U.S. The incidence rates among white women nationally and in Louisiana have been declining. They are also falling among black women in the U.S. but not in Louisiana. Because of early detection and improved treatment, mortality rates have been declining among white women and among U.S. black women. In Louisiana, however, they are rising for black women. Black women in Louisiana are more likely to be diagnosed with advanced disease than those in the U.S. (41% vs. 37%), so continued efforts to expand early detection programs, followed by timely and appropriate treatment, will undoubtedly improve survival. According to the American Cancer Society, the most important risk factor for breast cancer is age. Family history, a long menstrual history, never having had children, having a first child after age 30, recent use of oral contraceptives, overweight status after menopause, high-dose radiation to the chest, use of postmenopausal hormone therapy (especially combined estrogen and progestin), physical inactivity, and daily consumption of alcohol also increase the likelihood of developing breast cancer. Tamoxifen and raloxifene are recommended for women at high risk to avoid developing the disease.9

0

20

40

60

80

100

120

140

160

white women black women* Louisiana U.S.

Figure 5. Prostate Cancer

Incidence Rates per 100,000

Incidence Mortality

0

40

80

120

160

200

240

280

white men black men Louisiana U.S.#

# U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. Prostate cancer is the most commonly diagnosed cancer among men, but because of its relatively favorable prognosis it ranks second for mortality among men. Prostate cancer incidence and mortality are markedly higher among African-American men than among white men, but the reasons for these disparities are not fully understood. The well-established risk factors are age, ethnicity, and family history of prostate cancer. International studies suggest that a diet high in saturated fat may also be a risk factor, the American Cancer Society reports.9 The PSA test, which measures a prostate-specific antigen in the blood, was introduced in the late 1980s and permits the early detection of prostate cancer, before symptoms are noticeable. Because its effectiveness in improving survival and quality of life is still controversial, major scientific and medical organizations recommend that men discuss the PSA test with their physicians.

Over the past 25 years, five-year survival has risen from 69% to almost 99%, and this improvement is attributed both to advances in treatment and to early detection and diagnosis of asymptomatic prostate cancers. Although men with disease that is localized or has spread only regionally have an almost 100% five-year survival rate, those with distant metastasis have a 32% five-year survival.6

0

40

80

120

160

200

240

280

white men black men Louisiana U.S.

Figure 6. Cervical Cancer

Average Annual Rates per 100,000

Incidence Mortality

# U.S. rates are from the SEER Program (17 regions) of the National Cancer Institute. * Louisiana rates differ significantly (p < 0.05) from the U.S. rates.

In Western countries, screening programs using Pap tests allow precancerous lesions to be detected and removed before they become invasive. Once identified with Pap tests, cancers can be detected and treated before they spread. In developing countries, however, cervical malignancies are still an important cancer. Deaths from cervical cancer have fallen markedly in the past 40 years. For example, U.S. mortality rates have fallen from 6.7 per 100,000 in 1969 to 2.2 in 2005 for white women and from 17.8 in 1969 to 4.4 in 2005. Louisiana rates for white women approximate national rates, but African-American women still experience significantly higher incidence and mortality than their counterparts nationally even though Louisiana African-American women have similar rates for pap testing in the preceding three years (88% vs 87%).11 The Louisiana Breast and Cervical Screening Program, at the LSU Health Sciences Center in New Orleans (http://labchp.lsuhsc.edu/Services_2.htm), is making pap testing avail-able to women without health insurance. Risk factors for cervical cancer, according to the American Cancer Society, include infection with certain types of human papillomavirus (HPV), having sex at an early age or with multiple partners, immunosuppression, having a large number of children, cigarette smoking, and nutritional factors.9 In 2006 the U.S. Food and Drug Administration approved the use of Gardasil®, a vaccine to prevent the most common HPV infections that cause cervical cancer, for use by women aged 9-26.

0

5

10

15

20

white women black women*

Louisiana U.S. #

0

5

10

15

20

white women black women*

Louisiana U.S.

Figure 7. Tobacco-Related Cancer, 2001-2005


0

50

100

150

200

250

whitemen*

blackmen*

whitewomen*

blackwomen*

Louisiana U.S.

# U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. * The Louisiana rate differs significantly from the U.S. rate (p < 0.05).

The American Cancer Society reports that tobacco use is a risk factor for cancers of the lip, oral cavity and pharynx, esophagus, stomach, pancreas, lung, cervix, bladder, and kidney and for acute myeloid leukemia.9 Together, these account for about a third of new cancers and almost half of cancer deaths each year in Louisiana and the U.S.. The incidence of tobacco-related cancers is significantly higher in Louisiana than in the U.S. for men and white women, and mortality from these diseases is significantly higher in Louisiana for all four race/sex groups. According to the CDC’s Behavioral Risk Factor Survey, Louisiana ranks eighth in the prevalence of smoking. Twenty-six percent of Louisiana men smoke, vs. 19% nationwide; among women, the difference is smaller: 19% vs. 18%.11

0

50

100

150

200

250


blackwomen

Louisiana U.S.

Tables

Primary Site All Races Whites Blacks

Totals Males Females Totals Males Females Totals Males Females

Invasive Cancers

All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 21,047 11,403 9,644 15,242 8,261 6,981 5,596 3,022 2,574

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 531 383 147 388 278 110 137 102 35 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 29 24 5 28 23 5 1 1 0 Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 127 90 38 102 71 32 24 19 5 Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 50 32 19 36 24 12 14 7 7 Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 40 31 9 30 23 7 10 9 1 Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 89 54 35 62 37 25 26 17 9 Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 31 22 10 19 12 7 11 8 3 Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 83 68 15 61 50 11 22 18 4 Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 23 17 6 13 10 4 9 7 2 Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 43 34 8 27 21 6 15 13 2 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 15 12 3 10 8 2 5 4 1

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4,160 2,265 1,895 2,857 1,579 1,277 1,259 659 600 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 218 174 45 151 121 30 66 52 15 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 353 210 142 198 123 75 150 85 65 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 94 49 45 59 30 30 33 18 15 Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2,459 1,278 1,180 1,741 928 812 697 338 359 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1,791 899 892 1,252 644 608 524 246 278 Rectum and Rectosigmoid Junction‐‐‐‐ 668 380 289 489 284 205 173 92 82 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 60 26 34 46 20 26 13 6 7 Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 272 198 74 175 126 49 89 66 23 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 257 191 65 164 121 43 85 64 21 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 15 7 8 10 4 6 4 2 2 Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 50 17 33 31 11 21 18 6 12 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 65 32 33 48 24 24 16 7 9 Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 548 268 280 377 188 189 167 78 89 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 11 5 6 9 5 4 2 0 2 Peritoneum, Omentum and Mesentery‐‐‐‐‐ 17 1 16 15 1 14 3 0 3 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 13 6 6 8 3 5 5 3 2

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3,743 2,269 1,474 2,741 1,612 1,129 979 644 335 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 33 19 14 23 14 9 10 5 5 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 258 206 52 168 132 35 88 72 16 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3,441 2,037 1,404 2,542 1,460 1,082 879 565 314 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1 1 0 1 1 0 0 0 0 Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 10 6 4 8 5 3 2 1 1

Bones and Joints‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 35 19 16 24 13 12 11 6 5 Soft Tissue (Incl. heart)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 149 77 72 102 57 45 45 19 26

Skin (Excl. basal and squamous)‐‐‐‐‐‐‐‐‐‐‐ 581 347 235 542 328 214 24 12 12 Melanoma of the Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 514 308 206 490 297 193 12 5 6 Other Non‐Epithelial Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 67 39 28 53 31 21 13 7 6

Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2,869 26 2,843 2,039 18 2,021 809 7 802

Table A1. Average Annual Number of Cancer Cases, 2001‐2005, Louisiana

Female Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1,013 ‐‐ 1013 703 ‐‐ 703 298 ‐‐ 298 Cervix Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 220 ‐‐ 220 123 ‐‐ 123 94 ‐‐ 94 Corpus and Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 421 ‐‐ 421 300 ‐‐ 300 117 ‐‐ 117 Corpus Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 406 ‐‐ 406 291 ‐‐ 291 110 ‐‐ 110 Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16 ‐‐ 16 9 ‐‐ 9 7 ‐‐ 7 Ovary‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 280 ‐‐ 280 214 ‐‐ 214 64 ‐‐ 64 Vagina‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 20 ‐‐ 20 14 ‐‐ 14 6 ‐‐ 6 Vulva‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 60 ‐‐ 60 46 ‐‐ 46 13 ‐‐ 13 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 11 ‐‐ 11 6 ‐‐ 6 4 ‐‐ 4

Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3,402 3402 ‐‐ 2,332 2,332 ‐‐ 1024 1,024 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3,283 3283 ‐‐ 2,230 2,230 ‐‐ 1007 1,007 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 99 99 ‐‐ 88 88 ‐‐ 11 11 ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 17 17 ‐‐ 12 12 ‐‐ 6 6 ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 3 ‐‐ 2 2 ‐‐ 1 1 ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1,617 1,093 524 1,302 899 402 303 186 117 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 841 628 213 714 545 169 120 78 42 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 736 442 294 555 334 220 177 105 72 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 28 18 9 24 16 8 4 2 2 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12 5 6 9 4 5 3 1 1

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 30 17 13 26 15 11 4 2 2

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 255 147 108 203 118 85 49 26 23 Brain‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 242 141 102 193 113 80 46 25 21 Cranial Nerves and Other NS‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 13 6 6 10 5 5 3 1 1

Endocrine System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 356 95 261 282 80 202 67 14 54 Thyroid‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 327 81 246 262 70 193 59 10 49 Thymus and Other Endocrine‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 29 14 15 20 10 10 9 4 5

Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 958 510 447 762 405 357 187 101 87 Hodgkin Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 128 72 56 98 56 42 28 15 13 Non‐Hodgkin lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 830 439 391 664 349 314 159 86 74

Multiple Myeloma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 281 151 129 149 82 67 129 68 61

Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 525 301 224 405 236 169 115 63 52 Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 246 146 100 197 117 80 48 29 19 Acute Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 52 31 22 39 24 15 13 7 6 Chronic Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 175 103 72 142 83 59 32 20 12 Other Lymphocytic Leukemia ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 19 12 7 16 11 6 2 2 1 Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 234 130 104 178 101 77 54 28 26 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 146 79 66 112 63 49 32 16 17 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 10 4 5 7 3 4 2 1 1 Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 70 42 28 52 31 21 17 10 7 Other Myeloid/Monocytic Leukemia‐‐‐‐ 9 5 4 7 4 3 2 1 1 Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 44 25 19 30 18 13 14 7 7 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16 9 7 11 6 5 5 2 2 Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 28 16 12 19 11 8 9 5 4

Mesothelioma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 53 42 11 44 34 9 9 7 2

Kaposi Sarcoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 22 17 4 13 10 3 8 7 1

Ill‐Defined and Unknown Sites‐‐‐‐‐‐‐‐‐‐‐‐ 468 242 226 327 165 162 137 74 63

In Situ Cancers (not included above) Breast In Situ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 537 5 532 395 4 392 137 1 136

‐‐ Not applicable


Totals Males Females Totals Males Females Totals Males Females

Invasive Cancers

All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.5 3.4 1.5 2.5 3.4 1.6 2.4 3.4 1.4 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 0.1 0.2 0.3 0.1 0.0 0.0 0.0 Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.8 0.4 0.7 0.9 0.5 0.4 0.6 0.2 Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.3 Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.1 0.2 0.3 0.1 0.2 0.3 0.1 Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.4 0.4 0.4 0.4 0.5 0.6 0.3 Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.3 0.1 Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.6 0.2 0.4 0.6 0.2 0.4 0.6 0.2 Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.1 0.2 0.3 0.1 0.3 0.4 0.1 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 19.8 19.9 19.7 18.7 19.1 18.3 22.5 21.8 23.3 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.0 1.5 0.5 1.0 1.5 0.4 1.2 1.7 0.6 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.7 1.8 1.5 1.3 1.5 1.1 2.7 2.8 2.5 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.4 0.5 0.4 0.4 0.4 0.6 0.6 0.6 Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 11.7 11.2 12.2 11.4 11.2 11.6 12.5 11.2 14.0 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8.5 7.9 9.2 8.2 7.8 8.7 9.4 8.2 10.8 Rectum and Rectosigmoid Junction‐‐‐‐ 3.2 3.3 3.0 3.2 3.4 2.9 3.1 3.0 3.2 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 0.3 0.2 0.4 0.3 0.2 0.4 0.2 0.2 0.3 Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 1.3 1.7 0.8 1.1 1.5 0.7 1.6 2.2 0.9 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.7 0.7 1.1 1.5 0.6 1.5 2.1 0.8 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.3 0.2 0.1 0.3 0.3 0.2 0.5 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.6 2.4 2.9 2.5 2.3 2.7 3.0 2.6 3.5 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 Peritoneum, Omentum and Mesentery‐‐‐‐‐ 0.1 0.0 0.2 0.1 0.0 0.2 0.0 0.0 0.1 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 17.8 19.9 15.3 18.0 19.5 16.2 17.5 21.3 13.0 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.8 0.5 1.1 1.6 0.5 1.6 2.4 0.6 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16.4 17.9 14.6 16.7 17.7 15.5 15.7 18.7 12.2 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0

Bones and Joints‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 Soft Tissue (Incl. heart)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 0.7 0.7 0.7 0.7 0.7 0.8 0.6 1.0

Skin (Excl. basal and squamous)‐‐‐‐‐‐‐‐‐‐‐ 2.8 3.0 2.4 3.6 4.0 3.1 0.4 0.4 0.5 Melanoma of the Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.4 2.7 2.1 3.2 3.6 2.8 0.2 0.2 0.2 Other Non‐Epithelial Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.3 0.3 0.3 0.4 0.3 0.2 0.2 0.2

Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 13.6 0.2 29.5 13.4 0.2 28.9 14.5 0.2 31.2

Table A2. Percent Distribution of Cancer Cases by Primary Site, Race and Sex, 2001‐2005, Louisiana

Female Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.8 ‐‐ 10.5 4.6 ‐‐ 10.1 5.3 ‐‐ 11.6 Cervix Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.0 ‐‐ 2.3 0.8 ‐‐ 1.8 1.7 ‐‐ 3.6 Corpus and Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.0 ‐‐ 4.4 2.0 ‐‐ 4.3 2.1 ‐‐ 4.5 Corpus Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.9 ‐‐ 4.2 1.9 ‐‐ 4.2 2.0 ‐‐ 4.3 Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ‐‐ 0.2 0.1 ‐‐ 0.1 0.1 ‐‐ 0.3 Ovary‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.3 ‐‐ 2.9 1.4 ‐‐ 3.1 1.1 ‐‐ 2.5 Vagina‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ‐‐ 0.2 0.1 ‐‐ 0.2 0.1 ‐‐ 0.2 Vulva‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 ‐‐ 0.6 0.3 ‐‐ 0.7 0.2 ‐‐ 0.5 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ‐‐ 0.1 0.0 ‐‐ 0.1 0.1 ‐‐ 0.2

Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16.2 29.8 ‐‐ 15.3 28.2 ‐‐ 18.3 33.9 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 15.6 28.8 ‐‐ 14.6 27.0 ‐‐ 18.0 33.3 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.5 0.9 ‐‐ 0.6 1.1 ‐‐ 0.2 0.4 ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 ‐‐ 0.1 0.1 ‐‐ 0.1 0.2 ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 ‐‐ 0.0 0.0 ‐‐ 0.0 0.0 ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7.7 9.6 5.4 8.5 10.9 5.8 5.4 6.2 4.5 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.0 5.5 2.2 4.7 6.6 2.4 2.1 2.6 1.6 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.5 3.9 3.1 3.6 4.0 3.2 3.2 3.5 2.8 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.3 1.1 1.3 1.4 1.2 0.9 0.9 0.9 Brain‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.2 1.1 1.3 1.4 1.1 0.8 0.8 0.8 Cranial Nerves and Other NS‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1

Endocrine System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.7 0.8 2.7 1.8 1.0 2.9 1.2 0.5 2.1 Thyroid‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.6 0.7 2.6 1.7 0.8 2.8 1.0 0.3 1.9 Thymus and Other Endocrine‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2

Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.6 4.5 4.6 5.0 4.9 5.1 3.3 3.3 3.4 Hodgkin Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.6 0.6 0.6 0.7 0.6 0.5 0.5 0.5 Non‐Hodgkin lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.9 3.8 4.1 4.4 4.2 4.5 2.8 2.8 2.9

Multiple Myeloma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.3 1.3 1.3 1.0 1.0 1.0 2.3 2.2 2.4

Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.5 2.6 2.3 2.7 2.9 2.4 2.1 2.1 2.0 Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.3 1.0 1.3 1.4 1.1 0.9 0.9 0.7 Acute Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.2 Chronic Lymphocytic Leukemia ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.8 0.9 0.7 0.9 1.0 0.8 0.6 0.7 0.5 Other Lymphocytic Leukemia ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 1.1 1.1 1.1 1.2 1.2 1.1 1.0 0.9 1.0 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 0.7 0.7 0.7 0.8 0.7 0.6 0.5 0.6 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.4 0.3 0.3 0.4 0.3 0.3 0.3 0.3 Other Myeloid/Monocytic Leukemia‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2

Mesothelioma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.4 0.1 0.3 0.4 0.1 0.2 0.2 0.1

Kaposi Sarcoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.2 0.0

Ill‐Defined and Unknown Sites‐‐‐‐‐‐‐‐‐‐‐‐ 2.2 2.1 2.3 2.1 2.0 2.3 2.5 2.4 2.5



Total Males Females Total Males Females Total Males FemalesInvasive Cancers All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 491.3 616.9 404.2 485.4 596.7 407.7 515.9 692.3 401.7

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12.2 19.6 6.2 12.3 19.2 6.4 12.1 21.1 5.3 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 1.3 0.2 0.9 1.6 0.3 ^ ^ ^ Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.9 4.5 1.6 3.3 4.8 1.9 2.1 3.7 0.8 Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.8 0.8 1.2 1.9 0.7 1.3 1.8 1.1 Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.0 1.6 0.4 1.0 1.6 0.5 0.9 1.7 ^ Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.0 2.8 1.4 1.9 2.6 1.4 2.3 3.5 1.4 Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 1.1 0.4 0.6 0.8 0.4 1.0 1.7 ^ Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.8 3.2 0.6 1.8 3.1 0.6 1.8 3.3 0.6 Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.5 0.8 0.2 0.4 0.6 0.2 0.7 1.4 ^ Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.0 1.9 0.3 0.9 1.6 0.4 1.4 2.9 ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.6 ^ 0.3 0.6 ‐‐ 0.4 0.9 ^

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 97.5 123.3 77.9 90.6 115.3 71.3 118.7 150.2 96.8 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.1 9.1 1.8 4.8 8.6 1.7 5.9 10.9 2.3 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8.4 11.7 5.9 6.2 9.0 4.1 14.7 20.7 10.8 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.1 2.5 1.9 1.9 2.1 1.7 3.0 3.9 2.4 Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 57.6 70.1 48.4 55.3 68.2 45.4 65.5 77.4 57.4 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 42.2 50.2 36.4 39.9 48.2 33.7 49.7 57.7 44.5 Rectum and Rectosigmoid Junction‐‐‐‐ 15.4 19.9 11.9 15.4 20.0 11.7 15.8 19.7 12.9 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 1.4 1.3 1.4 1.5 1.3 1.6 1.2 1.2 1.2 Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 6.3 10.4 3.1 5.6 9.0 2.8 7.8 13.5 3.7 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.9 10.0 2.7 5.2 8.7 2.5 7.4 12.9 3.3 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.4 0.4 0.3 0.3 0.3 0.5 ^ ^ Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.0 1.3 1.0 0.8 1.1 1.7 1.5 1.9 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.5 1.9 1.3 1.5 1.9 1.3 1.5 1.7 1.4 Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 13.0 14.7 11.6 11.9 13.6 10.5 16.4 18.4 14.9 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.3 0.3 0.3 0.3 0.3 ^ ^ ^ Peritoneum, Omentum and Mesentery‐‐‐‐‐ 0.4 ^ 0.6 0.4 ^ 0.7 ^ 0.0 ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.4 0.3 0.3 0.2 0.3 0.5 ^ ^

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 87.5 123.1 61.2 86.5 116.4 64.2 91.3 147.1 53.3 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 0.8 1.0 0.6 0.7 0.9 0.5 0.9 1.0 0.8 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.8 10.3 2.2 5.2 8.9 2.1 7.7 15.3 2.3 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 80.6 111.4 58.2 80.3 106.1 61.4 82.5 130.5 50.2 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ 0.0 ^ ^ ^ Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.2 0.3 0.4 ^ ^ ^ ^



Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 67.0 1.3 120.9 65.7 1.3 120.5 71.3 1.5 123.0

Table B. Average Annual Cancer Incidence Rates,1 2001‐2005, Louisiana


Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 80.1 186.2 ‐‐ 74.0 168.3 ‐‐ 99.0 246.5 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 77.3 180.3 ‐‐ 70.4 161.0 ‐‐ 97.7 243.5 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.3 4.7 ‐‐ 3.1 6.3 ‐‐ 0.7 1.6 ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 1.0 ‐‐ 0.4 0.9 ‐‐ 0.5 1.3 ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ‐‐ ^ ^ ‐‐ ^ ^ ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 37.5 59.9 21.5 40.9 65.6 22.7 28.0 42.4 18.3 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 19.7 35.6 8.7 22.4 40.6 9.4 11.6 19.3 6.7 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16.9 23.0 12.1 17.5 23.4 12.6 15.7 22.4 11.1 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 1.1 0.4 0.7 1.2 0.4 0.4 ^ ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.3 0.3 0.3 0.3 0.3 ^ ^ ^

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 0.9 0.6 0.8 1.1 0.7 0.3 ^ ^

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.8 7.5 4.5 6.7 8.5 5.2 3.8 4.6 3.1 Brain‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.5 7.2 4.2 6.3 8.2 4.9 3.6 4.4 2.9 Cranial Nerves and Other NS‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.3 0.3 0.3 0.4 0.3 ^ ^ ^



Multiple Myeloma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 6.6 8.4 5.3 4.8 6.0 3.8 12.4 16.4 9.7

Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12.2 16.2 9.3 13.0 17.4 9.8 10.2 13.4 7.9 Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.7 7.8 4.2 6.3 8.5 4.6 4.3 6.2 3.1 Acute Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 1.4 1.0 1.4 1.7 1.1 0.9 0.9 0.8 Chronic Lymphocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.1 5.8 2.9 4.4 6.1 3.2 3.3 5.0 2.1 Other Lymphocytic Leukemia ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.6 0.3 0.5 0.7 0.3 ^ ^ ^ Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 5.4 6.9 4.3 5.7 7.3 4.5 4.5 5.6 3.8 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.3 4.3 2.7 3.6 4.6 2.8 2.7 3.2 2.4 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.3 ^ 0.3 ^ ^ ^ Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.6 2.2 1.2 1.7 2.2 1.2 1.5 2.1 1.0 Other Myeloid/Monocytic Leukemia‐‐‐‐ 0.2 0.2 0.2 0.2 0.2 ^ ^ ^ ^ Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.1 1.5 0.8 1.0 1.5 0.7 1.3 1.7 1.1 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.3 0.4 0.5 0.3 0.5 ^ ^ Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 0.7 1.0 0.5 0.6 1.0 0.4 0.8 1.0 0.7

Mesothelioma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.3 2.4 0.5 1.4 2.6 0.5 0.8 1.6 ^

Kaposi Sarcoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.5 1.0 0.2 0.5 0.8 0.2 0.6 1.3 ^


In Situ Cancers (not included above) Breast In Situ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12.4 0.2 22.7 12.7 0.3 23.7 12.0 -- 20.9

1. Rates per 100,000, age adjusted to the U.S. 2000 standard. See "Calculation of 2005 rates" in Introduction.

^ Rates are not generated for cells with counts less than 16. ‐‐ Not applicable

Non‐ Melanoma Oral

Hodgkin of the Cavity &

Lymphoma Skin Pharynx

Louisiana 596.7 161.0 106.2 68.2 40.6 24.7 23.4 20.5 19.3 17.4 13.6

Acadia 579.4 150.7 116.3 78.1 32.6 29.2 18.1 ^ 23.2 ^ ^

Allen 554.0 141.8 112.0 50.3 ^ ^ ^ ^ ^ ^ ^

Ascension 556.9 168.3 96.5 70.9 39.9 23.4 24.8 18.3 ^ ^ ^

Assumption 597.1 156.3 108.5 60.3 ^ ^ ^ ^ ^ ^ ^

Avoyelles 589.1 171.2 110.2 95.9 28.9 25.0 ^ ^ ^ ^ ^

Beauregard 583.5 163.7 120.5 58.1 45.0 27.9 ^ ^ ^ ^ ^

Bienville 574.2 154.1 115.9 78.2 ^ ^ ^ ^ ^ ^ ^

Bossier 655.1 169.7 125.9 63.1 42.3 29.1 24.1 29.7 24.7 17.9 11.6

Caddo 613.8 177.8 106.7 66.9 43.9 21.7 21.3 25.6 17.3 24.1 11.9

Calcasieu 630.9 188.5 111.7 62.0 37.4 28.0 24.7 22.1 21.9 17.2 10.8

Caldwell 618.3 147.9 140.8 100.7 ^ ^ ^ ^ ^ ^ ^

Cameron 557.2 107.9 127.7 ^ ^ ^ ^ ^ ^ 0.0 ^

Catahoula 517.8 175.9 94.5 ^ ^ ^ ^ ^ ^ ^ ^

Claiborne 547.0 159.2 79.9 79.5 ^ ^ ^ ^ ^ ^ ^

Concordia 422.5 120.3 119.4 50.0 ^ ^ ^ ^ ^ ^ ^

De Soto 661.6 219.1 117.2 78.4 ^ ^ ^ ^ ^ ^ ^

East Baton Rouge 558.6 174.8 82.8 58.4 38.5 22.1 23.0 23.2 17.9 19.7 13.4

East Carroll 680.9 190.7 ^ ^ ^ 0.0 ^ ^ ^ ^ ^

East Feliciana 591.6 162.8 110.4 65.3 ^ ^ ^ ^ ^ ^ ^

Evangeline 599.8 167.5 113.5 55.6 35.6 32.8 ^ ^ ^ ^ ^

Franklin 655.3 196.2 130.4 ^ 63.2 ^ ^ ^ ^ ^ ^

Grant 534.9 142.0 113.3 ^ 43.4 ^ ^ ^ ^ ^ ^

Iberia 623.8 180.3 122.6 69.5 43.0 ^ 19.0 16.9 16.1 15.5 ^

Iberville 617.3 134.8 130.6 56.6 49.7 ^ ^ ^ ^ ^ ^

Jackson 545.9 139.3 136.0 67.1 ^ ^ ^ ^ ^ ^ ^

Jefferson 561.1 125.4 105.1 61.4 41.4 24.8 26.5 20.3 17.2 13.4 16.5

Jefferson Davis 668.5 204.7 125.8 54.4 ^ 42.8 ^ ^ ^ ^ ^

Lafayette 647.5 194.6 107.5 76.4 46.4 24.2 26.3 20.8 15.6 21.9 10.4

Lafourche 575.0 158.0 86.8 58.4 48.8 22.1 28.6 11.4 18.5 17.4 15.2

La Salle 577.6 161.8 143.5 69.0 ^ ^ ^ ^ ^ ^ ^

Lincoln 502.9 151.1 81.3 82.7 34.0 ^ ^ ^ ^ ^ ^

Average Annual Incidence Rates1 by Louisiana Parish

Table C1. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Males

All Sites Prostate LungColon &

RectumBladder

2 Kidney Leukemia Pancreas

Non‐ Melanoma Oral

Hodgkin of the Cavity &

Lymphoma Skin Pharynx

Livingston 605.6 144.0 112.7 82.1 42.6 22.1 28.0 20.1 23.6 15.5 12.3

Madison 431.9 156.2 ^ ^ 0.0 ^ ^ ^ ^ ^ 0.0

Morehouse 667.9 172.0 126.6 93.4 45.2 ^ ^ ^ ^ ^ ^

Natchitoches 621.5 190.1 102.3 88.1 47.9 ^ ^ ^ ^ ^ ^

Orleans 564.7 151.2 81.4 57.7 39.4 28.1 22.5 21.3 20.9 14.4 13.7

Ouachita 594.2 141.2 104.5 71.1 45.8 22.0 17.8 29.0 27.1 18.9 15.9

Plaquemines 615.6 139.1 173.8 82.8 58.6 ^ ^ ^ ^ ^ ^

Pointe Coupee 614.7 163.7 100.5 89.5 ^ ^ ^ ^ ^ ^ ^

Rapides 620.5 174.8 111.3 75.9 38.2 19.3 27.9 21.1 15.2 23.3 22.1

Red River 690.6 122.9 109.2 ^ ^ ^ ^ ^ ^ ^ ^

Richland 667.9 158.2 164.2 68.6 ^ ^ ^ ^ ^ ^ ^

Sabine 615.7 182.0 118.7 90.1 31.2 ^ ^ ^ ^ ^ ^

St. Bernard 620.5 128.7 121.6 86.1 48.3 17.6 21.8 17.1 22.4 13.2 18.2

St. Charles 565.1 138.1 99.7 59.9 38.4 ^ 24.3 28.4 ^ ^ ^

St. Helena 524.7 ^ 146.9 ^ ^ ^ ^ ^ ^ 0.0 0.0

St. James 577.1 173.9 91.4 73.2 ^ ^ ^ 0.0 ^ ^ ^

St. John the Baptist 587.4 129.1 105.8 49.3 71.3 ^ ^ ^ ^ ^ ^

St. Landry 626.6 163.9 106.1 82.0 34.7 26.9 30.4 17.1 20.7 23.8 19.0

St. Martin 648.6 191.3 141.2 65.4 34.8 ^ ^ ^ ^ ^ ^

St. Mary 567.6 127.6 103.2 76.9 45.6 27.8 ^ ^ 20.0 ^ ^

St. Tammany 602.3 171.3 101.1 71.3 42.2 30.4 21.0 22.1 16.1 17.3 9.9

Tangipahoa 598.9 162.3 104.1 71.8 33.6 26.5 20.0 18.2 21.3 19.5 19.0

Tensas 584.8 ^ ^ ^ ^ ^ ^ 0.0 ^ ^ ^

Terrebonne 592.5 127.0 101.3 80.8 46.8 30.2 26.7 13.2 22.7 14.7 12.4

Union 570.9 152.3 103.0 39.9 ^ ^ ^ ^ ^ ^ ^

Vermilion 671.0 236.1 101.3 69.4 40.5 23.2 18.4 ^ 17.2 17.0 21.0

Vernon 583.7 125.6 126.1 93.0 28.9 ^ ^ ^ 26.5 25.4 ^

Washington 682.8 150.8 127.8 87.4 38.0 37.9 26.7 28.2 ^ ^ ^

Webster 686.6 213.4 128.3 69.1 32.8 27.2 31.7 26.2 25.2 ^ ^

West Baton Rouge 710.0 195.1 113.0 106.0 ^ ^ ^ ^ ^ ^ ^

West Carroll 683.6 212.5 122.0 ^ ^ ^ ^ ^ ^ ^ ^

West Feliciana 415.4 119.0 82.8 ^ ^ ^ ^ 0.0 ^ ^ ^

Winn 617.5 149.5 108.5 90.3 ^ ^ ^ ^ ^ ^ ^


2. Rates for bladder cancer include in situ cases. ^ Rates are not generated for cells with fewer than 16 cases in five years.

Leukemia PancreasAll Sites Prostate LungColon &

RectumBladder

2 Kidney

Non‐ Kidney Melanoma

Hodgkin & Renal of the

Lymphoma Pelvis Skin

Louisiana 407.7 120.5 61.4 45.4 18.0 17.8 12.8 12.7 12.6 11.8 10.5

Acadia 406.1 122.6 64.1 51.8 22.8 29.9 15.5 ^ ^ ^ ^

Allen 422.4 113.4 54.3 74.8 ^ ^ ^ ^ ^ ^ ^

Ascension 395.0 124.1 69.8 48.5 ^ 16.8 11.2 ^ ^ 13.6 ^

Assumption 391.9 128.7 52.2 44.2 ^ ^ ^ ^ ^ ^ ^

Avoyelles 374.3 94.3 63.4 47.5 ^ ^ ^ ^ ^ ^ ^

Beauregard 391.4 105.6 47.9 45.8 27.6 ^ ^ ^ ^ ^ ^

Bienville 393.8 111.9 62.5 ^ ^ ^ 0.0 ^ ^ ^ ^

Bossier 432.2 127.5 63.4 49.1 19.2 16.4 11.3 17.4 12.1 16.8 ^

Caddo 408.0 121.9 65.2 43.1 21.4 19.8 12.7 11.9 10.6 10.4 9.6

Calcasieu 426.4 118.2 70.1 51.3 18.6 21.1 11.5 12.9 12.3 15.6 10.5

Caldwell 405.7 96.1 70.5 ^ ^ ^ ^ ^ ^ ^ ^

Cameron 383.8 100.1 ^ ^ ^ ^ ^ ^ ^ ^ ^

Catahoula 483.3 127.1 ^ ^ ^ ^ ^ ^ ^ ^ ^

Claiborne 374.1 118.9 55.0 52.3 ^ ^ ^ ^ ^ ^ ^

Concordia 292.7 93.5 ^ ^ ^ ^ ^ ^ ^ ^ ^

De Soto 473.9 127.9 76.2 62.4 ^ ^ ^ ^ ^ ^ ^

East Baton Rouge 397.6 133.9 49.0 47.6 18.5 14.4 7.6 13.8 10.9 11.9 10.9

East Carroll 313.7 ^ ^ ^ ^ 0.0 0.0 ^ ^ ^ ^

East Feliciana 390.8 111.6 66.0 ^ ^ ^ ^ ^ ^ ^ ^

Evangeline 409.2 102.7 61.5 59.2 ^ ^ ^ ^ ^ ^ ^

Franklin 403.7 93.6 58.2 61.0 ^ ^ ^ ^ ^ ^ ^

Grant 353.1 90.0 50.4 ^ ^ ^ ^ ^ ^ ^ ^

Iberia 453.6 134.8 69.9 34.9 22.1 14.3 28.5 14.8 18.1 15.3 13.1

Iberville 376.9 95.9 70.4 43.7 ^ ^ ^ ^ ^ ^ ^

Jackson 404.8 133.5 63.0 ^ ^ ^ ^ ^ ^ ^ ^

Jefferson 409.1 124.4 64.3 41.4 17.2 20.7 11.2 13.1 13.6 9.6 7.1

Jefferson Davis 403.6 115.8 59.2 41.2 ^ 22.8 ^ ^ ^ ^ ^

Lafayette 412.7 126.2 65.8 43.1 19.7 15.7 16.0 10.9 11.2 10.4 14.6

Lafourche 346.5 115.2 45.0 33.2 18.2 15.2 8.6 12.1 17.4 ^ 8.8

La Salle 379.4 135.6 ^ 59.8 ^ ^ ^ ^ ^ ^ 0.0

Lincoln 386.2 101.5 44.8 72.1 30.0 ^ ^ ^ ^ ^ ^


Table C2. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Females

Uterus &

CorpusAll Sites Breast Lung

Colon &

RectumThyroid Ovary Pancreas

Non‐ Kidney Melanoma

Hodgkin & Renal of the

Lymphoma Pelvis Skin

Livingston 399.5 112.0 56.9 49.0 15.6 13.6 ^ 12.6 14.8 15.4 11.5

Madison 405.2 124.7 ^ ^ ^ ^ ^ 0.0 ^ ^ 0.0

Morehouse 391.4 87.3 65.3 53.4 ^ ^ ^ ^ ^ ^ ^

Natchitoches 413.1 90.6 69.3 42.3 36.2 ^ ^ ^ ^ ^ ^

Orleans 408.7 137.3 52.8 44.0 15.3 13.8 12.1 13.9 9.2 12.6 11.9

Ouachita 436.5 129.5 65.2 46.7 21.4 20.8 14.1 8.9 12.7 18.5 10.2

Plaquemines 457.1 120.6 78.1 51.5 ^ ^ ^ ^ ^ ^ ^

Pointe Coupee 310.5 91.3 41.5 41.1 ^ ^ 0.0 ^ ^ ^ ^

Rapides 394.7 97.1 54.7 51.4 16.4 20.5 16.9 12.7 15.9 9.2 10.9

Red River 293.4 ^ ^ ^ ^ ^ 0.0 ^ ^ ^ ^

Richland 379.8 74.6 73.9 ^ ^ ^ ^ ^ ^ ^ ^

Sabine 437.3 132.5 79.7 57.4 ^ ^ ^ ^ ^ ^ ^

St. Bernard 433.5 127.8 74.3 44.7 21.4 17.4 ^ 13.2 18.6 ^ 11.1

St. Charles 389.9 114.4 68.7 27.8 ^ 24.0 ^ ^ ^ ^ ^

St. Helena 363.8 ^ ^ ^ ^ ^ ^ 0.0 ^ ^ ^

St. James 361.7 112.3 ^ 67.3 ^ ^ ^ ^ ^ ^ ^

St. John the Baptist 403.4 123.5 63.7 48.6 ^ ^ ^ ^ ^ ^ ^

St. Landry 415.3 115.8 70.2 41.0 14.0 14.7 15.9 14.7 17.4 ^ 17.6

St. Martin 417.0 128.1 66.9 45.2 20.3 21.2 ^ ^ ^ ^ ^

St. Mary 416.4 99.3 66.9 54.5 20.4 23.7 ^ ^ ^ ^ ^

St. Tammany 460.2 139.8 68.8 46.3 17.4 20.8 21.2 15.1 13.9 16.7 8.8

Tangipahoa 386.4 115.6 56.6 45.9 17.2 24.4 ^ 11.8 11.0 11.3 ^

Tensas 292.6 ^ ^ ^ ^ ^ ^ ^ 0.0 0.0 0.0

Terrebonne 368.1 109.2 51.1 40.8 17.3 16.3 ^ 12.5 11.5 11.9 9.3

Union 416.5 130.9 66.8 31.5 ^ ^ ^ ^ ^ ^ ^

Vermilion 418.9 108.4 66.2 46.5 17.0 19.8 23.4 13.4 16.7 ^ 18.8

Vernon 391.5 98.2 55.6 45.0 ^ ^ ^ ^ 21.7 ^ ^

Washington 427.6 105.3 73.1 43.9 ^ ^ ^ ^ ^ ^ ^

Webster 427.1 124.9 70.0 51.2 ^ ^ ^ ^ ^ ^ ^

West Baton Rouge 411.5 117.6 60.5 57.3 ^ ^ ^ ^ ^ ^ ^

West Carroll 407.2 116.9 57.0 ^ ^ ^ ^ ^ ^ ^ ^

West Feliciana 387.8 159.0 ^ ^ ^ ^ 0.0 0.0 ^ ^ 0.0

Winn 385.1 69.6 62.2 57.9 ^ ^ ^ ^ ^ ^ ^


^ Rates are not generated for cells with fewer than 16 cases in five years.

Uterus &

CorpusAll Sites Breast Lung

Colon &

RectumThyroid Ovary Pancreas

Oral Non‐

Cavity & Hodgkin

Pharynx Lymphoma

Louisiana 692.3 243.5 130.6 77.4 22.4 21.2 20.7 19.3 18.4 16.7 16.4

Acadia 840.9 248.7 173.1 ^ ^ ^ ^ ^ 0.0 ^ ^

Allen 580.2 255.0 ^ ^ ^ ^ 0.0 ^ ^ ^ ^

Ascension 767.9 303.7 127.9 ^ ^ ^ ^ ^ ^ ^ ^

Assumption 650.7 203.4 ^ ^ ^ ^ ^ ^ ^ ^ ^

Avoyelles 783.4 251.9 200.6 100.5 ^ ^ ^ ^ ^ 0.0 ^

Beauregard 591.7 264.9 ^ ^ ^ ^ ^ ^ 0.0 ^ ^

Bienville 826.6 353.2 155.1 ^ ^ ^ ^ 0.0 ^ ^ ^

Bossier 561.3 209.3 96.0 64.2 ^ ^ ^ ^ ^ ^ ^

Caddo 691.3 238.6 124.5 88.3 19.7 24.9 25.9 14.8 18.9 19.1 11.4

Calcasieu 657.1 196.2 146.6 63.2 ^ 23.5 ^ 34.2 ^ 23.4 ^

Caldwell 1249.6 ^ ^ ^ ^ ^ 0.0 ^ 0.0 0.0 ^

Cameron ^ ^ ^ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Catahoula 734.6 ^ ^ ^ 0.0 ^ ^ 0.0 ^ 0.0 ^

Claiborne 783.2 301.6 158.8 ^ ^ ^ ^ ^ ^ ^ ^

Concordia 542.2 165.3 ^ ^ ^ ^ ^ ^ ^ ^ ^

De Soto 848.4 306.7 152.9 129.9 ^ ^ ^ ^ ^ ^ ^

East Baton Rouge 706.9 281.7 115.0 84.2 27.2 21.7 17.6 17.1 19.2 15.3 18.3

East Carroll 608.9 350.0 ^ ^ ^ ^ ^ 0.0 ^ 0.0 ^

East Feliciana 740.9 282.1 167.9 ^ ^ ^ 0.0 ^ ^ ^ ^

Evangeline 710.8 186.6 ^ 127.7 ^ ^ ^ ^ ^ ^ ^

Franklin 614.9 259.1 ^ ^ ^ 0.0 ^ ^ ^ ^ ^

Grant 911.9 343.2 ^ ^ ^ ^ ^ ^ ^ ^ 0.0

Iberia 754.7 281.9 151.9 57.3 ^ ^ ^ ^ ^ ^ ^

Iberville 769.2 243.6 145.2 82.7 ^ ^ ^ ^ ^ ^ ^

Jackson 741.3 268.7 ^ ^ ^ ^ ^ ^ ^ ^ ^

Jefferson 688.1 224.0 135.1 79.6 21.4 20.2 25.1 16.5 12.2 18.5 19.7

Jefferson Davis 738.5 355.2 ^ ^ 0.0 ^ ^ 0.0 ^ ^ ^

Lafayette 761.2 246.2 181.5 69.4 32.6 ^ ^ ^ ^ ^ ^

Lafourche 660.0 158.7 216.9 ^ ^ ^ ^ ^ ^ ^ ^

La Salle 808.0 ^ ^ ^ 0.0 0.0 0.0 0.0 ^ 0.0 0.0

Lincoln 576.6 213.3 158.9 ^ ^ ^ ^ ^ 0.0 0.0 ^

Table C3. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Males



RectumKidney Stomach Bladder

2 PancreasMultiple

Myeloma

Oral Non‐

Cavity & Hodgkin

Pharynx Lymphoma

Livingston 678.3 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^

Madison 591.3 159.1 164.1 ^ ^ ^ ^ ^ ^ 0.0 ^

Morehouse 710.3 282.1 120.0 ^ ^ ^ 0.0 ^ ^ ^ ^

Natchitoches 566.5 203.2 84.5 ^ ^ ^ ^ ^ ^ ^ ^

Orleans 682.8 215.5 126.6 84.9 21.5 19.7 22.3 24.6 16.8 22.3 16.6

Ouachita 644.8 262.4 95.5 80.5 ^ ^ ^ ^ ^ ^ ^

Plaquemines 731.0 250.8 ^ ^ ^ ^ ^ ^ ^ ^ ^

Pointe Coupee 809.7 265.1 176.8 ^ ^ ^ 0.0 ^ ^ ^ ^

Rapides 647.8 276.4 107.3 60.8 ^ ^ ^ ^ ^ ^ ^

Red River 539.1 ^ ^ ^ ^ ^ 0.0 0.0 ^ 0.0 ^

Richland 661.8 221.0 174.1 ^ ^ ^ ^ ^ ^ 0.0 0.0

Sabine 862.0 350.3 ^ ^ 0.0 ^ ^ ^ ^ 0.0 ^

St. Bernard 714.3 ^ ^ ^ ^ ^ ^ ^ ^ ^ 0.0

St. Charles 699.1 280.9 146.3 ^ ^ ^ ^ 0.0 ^ ^ ^

St. Helena 550.9 286.2 ^ ^ ^ ^ ^ ^ ^ 0.0 ^

St. James 632.7 285.4 ^ ^ ^ ^ ^ ^ ^ ^ ^

St. John the Baptist 748.3 242.0 128.4 111.0 ^ ^ ^ ^ ^ ^ ^

St. Landry 607.7 202.1 132.2 73.6 ^ ^ ^ ^ 32.8 ^ ^

St. Martin 747.1 251.5 161.2 91.8 ^ ^ ^ ^ ^ ^ ^

St. Mary 651.9 204.8 111.1 90.8 ^ ^ ^ ^ ^ ^ ^

St. Tammany 623.4 185.7 119.2 98.1 ^ ^ ^ ^ ^ ^ ^

Tangipahoa 740.7 309.0 162.0 62.1 ^ ^ ^ ^ ^ ^ ^

Tensas 562.8 ^ ^ ^ 0.0 0.0 0.0 ^ 0.0 ^ 0.0

Terrebonne 621.7 180.4 126.6 ^ ^ ^ ^ ^ ^ ^ 0.0

Union 747.1 264.6 173.5 ^ ^ ^ ^ ^ ^ 0.0 ^

Vermilion 745.2 206.1 157.6 ^ ^ ^ ^ ^ ^ 0.0 ^

Vernon 761.1 289.7 ^ ^ ^ ^ ^ ^ ^ 0.0 0.0

Washington 849.7 325.1 154.1 94.0 ^ ^ ^ ^ ^ ^ ^

Webster 928.8 360.6 186.8 89.5 ^ ^ ^ ^ ^ ^ ^

West Baton Rouge 781.3 283.4 159.9 ^ ^ ^ 0.0 ^ ^ ^ 0.0

West Carroll 838.4 ^ ^ ^ 0.0 0.0 0.0 ^ ^ 0.0 ^

West Feliciana 742.3 362.1 128.5 ^ ^ ^ ^ ^ 0.0 ^ ^

Winn 701.8 251.8 ^ ^ ^ ^ ^ 0.0 ^ ^ ^


2. Rates for bladder cancer include in situ cases. ^ Rates are not generated for cells with fewer than 16 cases in five years.


RectumKidney Stomach Bladder

2 PancreasMultiple

Myeloma

Louisiana 401.7 123.0 57.4 50.2 18.4 14.9 13.6 11.6 11.1 10.8 10.2

Acadia 461.2 112.4 85.8 90.1 ^ ^ ^ ^ ^ ^ 0.0

Allen 355.3 ^ ^ ^ ^ ^ 0.0 ^ ^ ^ ^

Ascension 484.8 175.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

Assumption 449.6 150.9 ^ ^ ^ ^ ^ ^ ^ ^ ^

Avoyelles 337.7 71.2 ^ ^ ^ ^ ^ 0.0 ^ ^ ^

Beauregard 328.2 ^ ^ ^ 0.0 0.0 ^ ^ 0.0 ^ ^

Bienville 396.0 130.1 ^ ^ ^ ^ ^ ^ 0.0 ^ ^

Bossier 352.2 105.0 49.0 ^ ^ ^ ^ ^ ^ ^ ^

Caddo 390.7 123.2 60.9 41.1 19.7 11.5 17.9 13.6 10.7 7.6 11.6

Calcasieu 400.2 107.6 73.9 65.1 ^ 21.0 17.2 ^ ^ ^ ^

Caldwell 422.6 ^ ^ 0.0 ^ 0.0 ^ ^ ^ ^ ^

Cameron ^ 0.0 ^ ^ 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Catahoula 512.1 ^ ^ ^ ^ ^ ^ 0.0 ^ 0.0 ^

Claiborne 494.6 174.0 95.3 ^ ^ ^ ^ ^ ^ ^ ^

Concordia 281.0 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^

De Soto 375.6 155.1 ^ ^ ^ ^ ^ ^ ^ ^ ^

East Baton Rouge 399.0 126.9 53.7 42.4 17.5 16.4 10.6 13.2 11.5 10.8 11.7

East Carroll 460.1 146.5 ^ ^ ^ ^ ^ ^ 0.0 ^ 0.0

East Feliciana 424.2 108.8 ^ ^ ^ ^ ^ ^ ^ 0.0 ^

Evangeline 397.5 112.5 ^ ^ ^ 0.0 ^ ^ ^ ^ ^

Franklin 350.8 132.0 ^ ^ ^ ^ 0.0 ^ 0.0 ^ ^

Grant 433.3 ^ ^ ^ ^ 0.0 0.0 ^ ^ 0.0 0.0

Iberia 436.0 157.3 53.6 48.2 ^ ^ ^ ^ ^ ^ ^

Iberville 414.2 157.8 ^ ^ ^ ^ ^ ^ ^ ^ ^

Jackson 447.6 ^ ^ ^ ^ ^ ^ 0.0 ^ 0.0 ^

Jefferson 392.7 121.2 51.5 50.6 17.0 ^ 13.3 13.1 9.6 14.1 10.0

Jefferson Davis 395.2 ^ ^ ^ ^ ^ ^ 0.0 ^ 0.0 ^

Lafayette 424.9 127.9 61.8 53.6 ^ 25.9 ^ ^ ^ ^ ^

Lafourche 391.9 114.5 ^ ^ ^ ^ ^ 0.0 ^ ^ ^

La Salle ^ ^ 0.0 ^ 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Lincoln 453.9 134.3 59.7 63.3 ^ ^ ^ ^ ^ ^ ^

Table C4. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Females


Uterus &

CorpusAll Sites Breast

Colon &

RectumLung Pancreas Cervix Stomach Ovary

Non‐

Hodgkin

Lymphoma

Kidney

Livingston 487.7 ^ ^ ^ ^ ^ ^ ^ 0.0 ^ 0.0

Madison 310.6 120.1 ^ ^ ^ ^ ^ ^ ^ 0.0 ^

Morehouse 325.3 90.5 ^ ^ ^ ^ ^ ^ ^ ^ ^

Natchitoches 350.0 85.5 54.8 ^ ^ ^ ^ ^ ^ ^ ^

Orleans 408.3 125.0 57.5 55.4 18.8 15.9 10.8 9.2 9.6 10.6 9.8

Ouachita 415.0 134.0 59.0 40.8 ^ ^ ^ ^ ^ ^ ^

Plaquemines 360.3 ^ ^ ^ ^ ^ 0.0 0.0 ^ ^ ^

Pointe Coupee 303.1 97.1 ^ ^ ^ ^ ^ ^ ^ ^ 0.0

Rapides 450.4 110.6 59.8 69.3 ^ ^ 21.2 ^ 21.6 ^ ^

Red River 345.5 ^ ^ ^ ^ 0.0 ^ ^ 0.0 0.0 ^

Richland 425.9 99.7 ^ ^ ^ ^ ^ ^ ^ ^ ^

Sabine 474.7 ^ ^ ^ ^ ^ 0.0 ^ ^ ^ 0.0

St. Bernard 452.7 ^ ^ ^ ^ 0.0 0.0 ^ ^ 0.0 ^

St. Charles 364.1 91.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

St. Helena 332.2 ^ ^ ^ ^ ^ ^ ^ ^ 0.0 ^

St. James 330.5 103.1 ^ ^ ^ ^ ^ ^ ^ ^ ^

St. John the Baptist 455.8 126.6 60.3 ^ ^ ^ ^ ^ ^ ^ ^

St. Landry 393.7 120.1 57.7 53.9 ^ ^ ^ ^ ^ ^ ^

St. Martin 399.6 134.8 72.0 ^ ^ ^ ^ ^ ^ ^ ^

St. Mary 434.6 135.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

St. Tammany 298.2 84.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

Tangipahoa 400.6 116.7 66.8 59.4 ^ ^ ^ ^ ^ ^ ^

Tensas 426.2 ^ ^ ^ ^ ^ ^ ^ 0.0 ^ ^

Terrebonne 415.0 140.6 ^ 83.6 ^ ^ ^ ^ ^ ^ ^

Union 324.7 122.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

Vermilion 455.7 156.9 ^ ^ ^ ^ ^ ^ ^ ^ ^

Vernon 449.3 ^ ^ ^ ^ ^ ^ ^ 0.0 ^ ^

Washington 426.3 81.6 90.3 60.1 ^ ^ ^ ^ ^ ^ 0.0

Webster 403.0 126.3 75.3 47.9 ^ ^ ^ ^ ^ ^ ^

West Baton Rouge 477.5 135.6 ^ ^ ^ ^ ^ ^ ^ ^ ^

West Carroll 539.0 ^ ^ ^ ^ ^ 0.0 ^ ^ ^ ^

West Feliciana 420.7 ^ ^ ^ ^ ^ ^ 0.0 0.0 ^ 0.0

Winn 531.0 205.9 ^ ^ ^ ^ ^ ^ ^ ^ ^


^ Rates are not generated for cells with fewer than 16 cases in five years.

Uterus &

CorpusAll Sites Breast

Colon &

RectumLung Stomach OvaryPancreas Cervix

Non‐

Hodgkin

Lymphoma

Kidney

New Baton South‐ South‐ North‐ North‐

U.S.3 Louisiana Orleans Rouge east west west east

Region Region Region Region Region Region

Invasive Cancers

All Sites Combined 551.4 596.7 ↑ 568.4 * 578.4 * 596.8 624.9 # 619.6 584.2 629.0 # 598.1

Prostate 156.7 161.0 ↑ 133.1 * 163.4 153.8 180.5 # 179.9 # 158.7 180.2 # 155.5

Lung and Bronchus 79.4 106.2 ↑ 100.1 96.8 * 102.8 111.2 115.5 114.7 112.3 112.0

Colon and Rectum 59.0 68.2 ↑ 63.0 * 66.8 70.8 73.6 59.3 * 75.6 70.6 70.3

Urinary bladder4 40.6 40.6 41.8 40.1 46.0 # 40.2 35.9 33.5 * 40.8 40.6

Non‐Hodgkin lymphoma 24.3 24.7 25.0 24.8 28.2 23.9 29.7 19.0 * 23.0 22.5

Kidney and renal pelvis 18.8 23.4 ↑ 24.6 23.9 23.7 22.8 23.5 23.1 24.4 18.7 *

Melanoma of the skin 28.5 20.5 ↓ 20.2 20.8 18.0 17.3 * 21.9 17.9 24.1 26.7 #

Oral cavity and Pharynx 15.8 19.3 ↑ 18.8 19.1 17.8 17.1 19.7 17.2 20.7 26.6 #

Leukemia 16.7 17.4 13.7 * 17.3 16.2 18.7 17.4 20.8 20.5 18.4

Pancreas 13.0 13.6 15.8 13.1 12.0 14.2 11.0 16.2 12.2 14.1

1. Rates per 100,000, age‐adjusted to the U.S. 2000 standard. See "Calculating 2005 Rates" in the Introduction.

2. See page ___ for a list of parishes in LTR regions.

3. U.S. incidence rate estimates are from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, 17 regions.

4. Bladder cases include in situ disease.

↑ or ↓ The rate is significantly higher or lower (p < 0.05) than the U.S. rate.

* The regional rate is significantly lower (p < 0.05) than the Louisiana rate.

# The regional rate is significantly higher (p < 0.05) than the Louisiana rate.

Primary SiteAcadiana

Region

Central

Region

Table D1. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Males

Average Annual Indidence Rates1 by Louisiana Tumor Registry Region

2




Invasive CancersAll Sites 423.6 407.7 ↓ 410.4 392.3 * 409.4 418.5 417.4 383.6 * 416.8 410.9

Breast 130.6 120.5 ↓ 128.1 # 123.0 123.5 120.1 115.2 98.7 * 121.3 113.4

Lung and Bronchus 54.9 61.4 ↑ 62.0 54.7 * 60.6 66.7 # 63.8 53.7 * 65.8 63.5

Colon and Rectum 43.2 45.4 ↑ 42.4 46.8 41.9 45.2 51.3 48.7 47.0 46.8

Uterus and Corpus 24.3 18.0 ↓ 17.1 17.3 16.3 18.9 18.9 14.7 20.8 21.8 #

Non‐Hodgkin lymphoma 17.1 17.8 18.3 16.9 18.2 18.8 19.9 17.0 16.4 16.3

Thyroid 14.1 12.8 ↓ 11.2 8.4 * 15.0 18.6 # 11.6 12.5 11.7 14.3

Ovary 14.1 12.7 ↓ 13.5 11.8 13.2 11.1 11.2 13.6 14.0 12.7

Kidney and Renal Pelvis 9.5 12.6 ↑ 13.1 11.6 14.5 13.5 13.1 13.3 11.4 10.2

Melanoma of the Skin 18.5 11.8 ↓ 10.2 12.3 12.1 9.4 * 15.3 # 10.4 13.0 15.4 #

Pancreas 10.0 10.5 9.0 10.4 10.2 15.4 # 10.7 11.4 9.0 8.1







Primary SiteCentral

Region

Acadiana

Region

Table D2. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Females

Average Annual Indidence Rates1 by Louisiana Tumor Registry Region

2




Invasive Cancers

All Sites 651.5 692.3 ↑ 683.1 718.2 689.4 703.9 645.9 676.1 712.5 661.5

Prostate 248.5 243.5 217.0 * 280.7 # 232.2 231.1 222.0 261.3 258.1 256.8

Lung and Bronchus 107.7 130.6 ↑ 128.3 126.0 136.0 145.1 133.2 126.7 129.1 126.5

Colon and Rectum 71.2 77.4 ↑ 84.0 76.2 76.8 80.9 59.4 73.8 82.3 60.7 *

Kidney and Renal Pelvis 21.3 22.4 21.3 26.6 26.1 23.9 18.5 17.2 21.1 19.4

Oral cavity and Pharynx 17.4 21.2 ↑ 20.3 24.3 17.6 20.2 23.9 19.4 24.2 17.4

Stomach 17.4 20.7 ↑ 23.2 18.2 21.4 19.9 ^ 17.9 22.9 19.0

Urinary Bladder4 20.4 19.3 23.4 17.9 16.6 20.5 27.2 ^ 15.1 16.1

Pancreas 16.2 18.4 ↑ 16.0 18.7 19.6 23.1 ^ 22.1 19.0 17.7

Non‐Hodgkin lymphoma 18.4 16.7 21.1 # 15.6 17.2 16.6 23.2 ^ 14.8 8.5 *

Myeloma 14.4 16.4 ↑ 17.2 18.6 13.0 15.3 ^ ^ 16.2 19.9









Region

Central

Region

Table D3. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Males

Average Annual Indidence Rates1 by Louisiana Tumor Registry Region2




Invasive Cancers

All Sites 398.9 401.7 405.7 405.1 380.7 420.8 394.9 419.9 388.6 396.7

Breast 117.5 123.0 ↑ 125.2 128.8 107.4 * 131.1 106.9 108.2 123.0 124.8

Colon and Rectum 54.5 57.4 56.1 57.1 51.8 58.7 68.3 54.7 62.3 54.8

Lung and Bronchus 54.6 50.2 ↓ 55.0 45.4 48.4 53.8 64.8 # 63.8 # 40.5 * 42.8

Uterus and Corpus 20.3 18.4 ↓ 18.5 18.8 19.6 16.7 17.0 14.0 17.8 22.8

Pancreas 14.3 14.9 14.8 15.9 13.8 18.2 18.3 13.8 10.6 * 16.1

Cervix 10.8 13.6 ↑ 11.3 13.3 13.9 10.1 15.8 19.8 16.9 16.0

Non‐Hodgkin lymphoma 12.1 11.6 10.0 11.8 9.2 16.5 # 13.9 11.1 11.7 11.5

Kidney and Renal Pelvis 10.1 11.1 9.8 10.8 14.8 13.0 ^ 17.2 # 9.6 11.1

Stomach 8.9 10.8 ↑ 11.0 11.0 15.1 11.5 ^ 11.2 9.0 10.5

Ovary 10.1 10.2 9.8 10.4 9.9 10.1 ^ 13.8 10.9 9.6








Region

Central

Region

Table D4. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Females

Average Annual Indidence Rates1 by Louisiana Tumor Registry Region2




All Sites Combined 551.4 596.7 ↑ 569.6 * 569.1 * 577.9 630.2 # 619.6 584.2 629.0 # 598.1 608.2

Prostate 156.7 161.0 ↑ 133.4 * 170.1 140.6 * 185.5 # 179.9 # 158.7 180.2 # 155.5 160.3

Lung and bronchus 79.4 106.2 ↑ 102.1 91.0 * 97.3 111.8 115.5 114.7 112.3 112.0 106.9

Colon and rectum 59.0 68.2 ↑ 63.4 62.9 67.2 73.3 59.3 * 75.6 70.6 70.3 75.4 #

Urinary bladder4 40.6 40.6 42.3 40.5 48.2 # 39.8 35.9 33.5 * 40.8 40.6 40.4

Non‐Hodgkin lymphoma 24.3 24.7 24.8 24.5 26.3 23.5 29.7 19.0 * 23.0 22.5 28.8

Kidney and renal pelvis 18.8 23.4 ↑ 24.3 23.0 26.0 23.2 23.5 23.1 24.4 18.7 * 22.9

Melanoma of the skin 28.5 20.5 ↓ 19.6 22.0 14.6 * 17.3 21.9 17.9 24.1 26.7 # 21.4

Oral cavity and pharynx 15.8 19.3 ↑ 18.9 17.6 18.9 16.8 19.7 17.2 20.7 26.6 # 19.1

Leukemia 16.7 17.4 13.6 * 17.2 16.0 19.0 17.4 20.8 20.5 18.4 17.2

Pancreas 13.0 13.6 15.8 12.5 12.3 14.5 11.0 16.2 12.2 14.1 12.5


2. See Appendix 5 for a list of parishes in each OPH region.




* The Industrial Corridor rate is significantly lower (p < 0.05) than the Louisiana rate.

# The Industrial Corridor rate is significantly higher (p < 0.05) than the Louisiana rate.

Table E1. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Males

Average Annual Incidence Rate1 by Louisiana Office of Public Health Regions2

Primary SiteCentral

Region

North‐

lake

Region

Acadiana

Region




All Sites 423.6 407.7 ↓ 411.9 392.3 * 374.7 * 418.8 417.4 383.6 * 416.8 410.9 425.5 #

Breast 130.6 120.5 ↓ 128.0 # 127.2 112.8 122.1 115.2 98.7 * 121.3 113.4 124.7

Lung and bronchus 54.9 61.4 ↑ 62.5 54.0 * 53.5 * 66.7 # 63.8 53.7 * 65.8 63.5 63.5

Colon and rectum 43.2 45.4 ↑ 42.6 46.5 40.9 44.5 51.3 48.7 47.0 46.8 46.2

Uterus and corpus 24.3 18.0 ↓ 17.1 17.5 16.4 18.8 18.9 14.7 20.8 21.8 # 16.7

Non‐Hodgkin lymphoma 17.1 17.8 18.4 15.5 18.2 18.3 19.9 17.0 16.4 16.3 19.6

Thyroid 14.1 12.8 ↓ 11.5 8.6 * 9.9 19.0 # 11.6 12.5 11.7 14.3 15.0

Ovary 14.1 12.7 ↓ 13.3 11.9 11.3 11.3 11.2 13.6 14.0 12.7 13.7

Kidney and renal pelvis 9.5 12.6 ↑ 13.2 11.2 14.2 13.6 13.1 13.3 11.4 10.2 13.7

Melanoma of the skin 18.5 11.8 ↓ 10.3 11.9 9.2 9.2 * 15.3 # 10.4 13.0 15.4 # 14.6

Pancreas 10.0 10.5 9.1 10.9 11.3 15.4 # 10.7 11.4 9.0 8.1 9.3







Table E2. Ten Most Commonly Diagnosed Cancers, 2001‐2005: White Females


Primary SiteCentral

Region

North‐

lake

Region

Acadiana

Region




All Sites 651.5 692.3 ↑ 683.7 725.0 667.5 710.3 645.9 676.1 712.5 661.5 705.4

Prostate 248.5 243.5 217.2 * 282.8 # 221.3 234.5 222.0 261.3 258.1 256.8 266.2

Lung and bronchus 107.7 130.6 ↑ 128.2 126.3 131.1 149.1 # 133.2 126.7 129.1 126.5 129.7

Colon and rectum 71.2 77.4 ↑ 83.9 79.1 71.5 79.8 59.4 73.8 82.3 60.7 * 77.0

Kidney and renal pelvis 21.3 22.4 21.9 28.3 18.9 25.1 18.5 17.2 21.1 19.4 23.6

Oral cavity and pharynx 17.4 21.2 ↑ 20.1 24.1 21.4 18.8 23.9 19.4 24.2 17.4 21.7

Stomach 17.4 20.7 ↑ 23.4 16.1 29.0 18.4 ^ 17.9 22.9 19.0 17.5

Urinary bladder4 20.4 19.3 23.4 19.0 13.7 20.6 27.2 ^ 15.1 16.1 18.0

Pancreas 16.2 18.4 ↑ 16.1 18.9 19.9 23.1 ^ 22.1 19.0 17.7 19.0

Non‐Hodgkin lymphoma 18.4 16.7 21.2 # 14.7 13.2 16.1 23.2 ^ 14.8 * 8.5 * 24.7

Multiple Myeloma 14.4 16.4 ↑ 17.0 18.2 ^ 16.4 ^ ^ 16.2 19.9 20.1





^ Rates are not calculated if fewer than 16 cases are diagnosed in the five‐year period.




Table E3. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Males


Primary SiteCentral

Region

North‐

lake

Region

Acadiana

Region




Invasive Cancers

All Sites 398.9 401.7 405.0 404.3 408.5 419.3 394.9 419.9 388.6 396.7 377.1

Breast 117.5 123.0 ↑ 125.0 130.4 124.6 130.7 106.9 108.2 123.0 124.8 99.5 *

Colon and rectum 54.5 57.4 55.9 53.3 52.0 60.3 68.3 54.7 62.3 54.8 64.4

Lung and bronchus 54.6 50.2 ↓ 54.8 43.0 48.6 55.4 64.8 # 63.8 # 40.5 * 42.8 51.2

Uterus and corpus 20.3 18.4 ↓ 18.4 20.0 22.2 16.7 17.0 14.0 17.8 22.8 12.7

Pancreas 14.3 14.9 14.9 16.6 15.5 17.3 18.3 13.8 10.6 * 16.1 13.7

Cervix 10.8 13.6 ↑ 11.2 12.2 10.8 10.9 15.8 19.8 16.9 16.0 19.4

Non‐Hodgkin lymphoma 12.1 11.6 9.9 12.0 11.7 16.0 13.9 11.1 11.7 11.5 ^

Kidney and renal pelvis 10.1 11.1 9.9 10.2 11.4 13.9 ^ 17.2 # 9.6 11.1 15.3

Stomach 8.9 10.8 ↑ 11.0 11.0 17.8 # 10.3 ^ 11.2 9.0 10.5 11.7

Ovary 10.1 10.2 9.8 10.8 14.9 9.5 ^ 13.8 10.9 9.6 ^




^ Rates are not calculated if fewer than 16 cases are diagnosed in the five‐year period.




Table E4. Ten Most Commonly Diagnosed Cancers, 2001‐2005: Black Females


North‐

lake

Region

Primary SiteCentral

Region

Acadiana

Region

Primary Site(Invasive cancers only)

U.S. La.Ind.

Corr.U.S. La.

Ind.

Corr.U.S. La.

Ind.

Corr.U.S. La.

Ind.

Corr.

All Sites Combined 551.4 596.7 ↑ 568.4 * 423.6 407.7 ↓ 395.1 651.5 692.3 ↑ 717.1 398.9 401.7 406.7

Oral Cavity and Pharynx 15.8 19.3 ↑ 17.2 6.1 6.4 6.2 17.4 21.2 ↑ 21.5 5.9 5.4 6.1

Esophagus 8.0 8.6 8.2 1.9 1.7 ^ 10.0 10.9 9.5 3.0 2.3 ^

Stomach 10.0 9.0 ↓ 8.4 4.7 4.1 ↓ 3.3 17.4 20.7 ↑ 20.5 8.9 10.8 ↑ 11.9

Colon and Rectum 59.0 68.2 ↑ 61.7 * 43.2 45.4 ↑ 46.9 71.2 77.4 ↑ 81.7 54.5 57.4 53.3

Colon 41.1 48.2 ↑ 43.2 32.4 33.7 ↑ 35.3 53.7 57.7 ↑ 61.9 42.7 44.5 41.4

Rectum 17.8 20.0 ↑ 18.4 10.8 11.7 ↑ 11.6 17.5 19.7 ↑ 19.8 11.8 12.9 11.9

Liver and Intrahepatic Bile Duct 8.2 9.0 ↑ 7.7 2.9 2.8 2.0 13.2 13.5 14.9 4.0 3.7 5.5

Pancreas 13.0 13.6 11.8 10.0 10.5 11.3 16.2 18.4 ↑ 18.6 14.3 14.9 16.7

Larynx 6.3 8.9 ↑ 5.5 * 1.4 2.1 ↑ ^ 10.9 15.3 ↑ 10.8 2.0 2.3 3.3

Lung and Bronchus 79.4 106.2 ↑ 91.3 * 54.9 61.4 ↑ 55.2 * 107.7 130.6 ↑ 121.8 54.6 50.2 ↓ 42.4 *

Melanoma of the Skin 28.5 20.5 ↓ 21.4 18.5 11.8 ↓ 11.3 1.1 1.3 ^ 0.9 1.0 ^

Breast 1.2 1.3 ^ 130.6 120.5 ↓ 126.9 1.6 1.5 ^ 117.5 123.0 ↑ 129.4

Cervix Uteri ‐‐ ‐‐ ‐‐ 8.2 8.2 5.9 * ‐‐ ‐‐ ‐‐ 10.8 13.6 ↑ 12.1

Uterus and corpus ‐‐ ‐‐ ‐‐ 24.3 18.0 ↓ 16.8 ‐‐ ‐‐ ‐‐ 20.3 18.4 ↓ 19.0

Ovary ‐‐ ‐‐ ‐‐ 14.1 12.7 ↓ 12.2 ‐‐ ‐‐ ‐‐ 10.1 10.2 11.6

Prostate 156.7 161.0 ↑ 166.1 ‐‐ ‐‐ ‐‐ 248.5 243.5 277.5 # ‐‐ ‐‐ ‐‐

Testis 6.3 6.3 6.4 ‐‐ ‐‐ ‐‐ 1.4 1.6 ^ ‐‐ ‐‐ ‐‐

Urinary Bladder4 40.6 40.6 42.5 10.0 9.4 9.8 20.4 19.3 17.7 7.7 6.7 6.7

Kidney and Renal Pelvis 18.8 23.4 ↑ 24.0 9.5 12.6 ↑ 11.6 21.3 22.4 26.7 10.1 11.1 11.3

Brain and Other Nervous System 8.4 8.5 8.2 6.0 5.2 6.1 4.7 4.6 ^ 3.6 3.1 3.6

Thyroid 4.9 4.8 2.8 * 14.1 12.8 ↓ 9.2 * 2.7 2.0 ^ 8.0 7.1 3.8 *

Hodgkin Lymphoma 3.3 3.9 ↑ 3.2 2.7 2.8 2.5 2.9 2.5 ^ 2.3 1.7 ^

Non‐Hodgkin Lymphoma 24.3 24.7 23.5 17.1 17.8 16.3 18.4 16.7 14.1 12.1 11.6 12.6

Multiple Myeloma 6.6 6.0 6.1 4.1 3.8 4.3 14.4 16.4 ↑ 17.6 9.8 9.7 11.6

Leukemia 16.7 17.4 17.7 9.9 9.8 8.7 13.0 13.4 15.6 8.0 7.9 10.5

1. Rates per 100,000, age adjusted to the U.S. 2000 standard

2. The Industrial Corridor comprises Ascenson, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes.

3. U.S incidence rate estimates are from the Surveillance, Epidemiology and end Results (SEER) Program of the National Cancer Institute, 17 regions.


^ Rates are not calculated if fewer than 16 cases are diagnosed in the five‐year period. ‐‐ Not applicable


* Industrial Corridor rate is significantly lower than the Louisiana rate. # Industrial Corridor rate is significantly higher than the Louisiana rate.

Table F. Average Annual Cancer Incidence Rates,1 2001‐2005: U.S., Louisiana, and Industrial Corridor2

White Males White Females Black Males Black Females


Total Males Females Total Males Females Total Males Females

All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 9435 5053 4381 6537 3491 3045 2844 1532 1312

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 153 112 41 100 70 30 52 41 11 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1 1 0 1 1 0 0 0 0 Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 28 19 9 21 14 7 7 6 2 Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 10 6 4 8 5 3 2 1 1 Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0 0 0 0 0 0 0 0 0 Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 23 16 7 14 9 4 9 6 3 Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 11 7 4 7 4 3 3 3 1 Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8 6 2 6 4 2 2 2 0 Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 14 10 4 9 6 3 5 4 1 Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5 4 1 3 2 1 2 2 0 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 52 42 10 31 24 7 21 18 3

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2247 1251 996 1487 838 649 740 401 339 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 193 152 40 134 107 27 58 45 13 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 214 130 84 106 66 41 104 62 42 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 15 7 8 11 4 6 4 2 2 Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 949 500 450 635 344 291 308 151 157 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 813 420 394 540 287 253 268 130 139 Rectum and Rectosigmoid Junction‐‐‐‐ 136 80 56 95 58 38 40 21 18 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 5 2 4 4 1 3 1 1 1 Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 287 186 102 192 119 73 91 63 28 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 254 171 84 167 109 59 82 59 24 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 33 15 18 25 11 14 8 4 4 Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 28 10 18 18 7 12 9 3 6 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 16 7 9 11 5 6 5 2 3 Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 514 247 267 357 177 180 154 69 85 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 1 2 2 1 1 0 0 0 Peritoneum, Omentum and Mesentery‐‐‐‐‐ 8 2 6 6 1 5 1 0 1 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 15 8 7 10 5 4 5 3 2

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2959 1809 1150 2135 1260 875 810 540 270 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 5 3 2 4 2 2 1 1 0 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 80 64 15 46 36 10 33 28 5 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2869 1738 1131 2080 1218 861 775 510 265 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 2 0 2 2 0 1 1 0 Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 2 1 2 1 1 1 1 0

Bones and Joints‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 31 16 15 20 10 10 10 6 4 Soft Tissue (Incl. heart)‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 50 25 25 36 18 18 14 7 7

Skin (Excl. basal and squamous)‐‐‐‐‐‐‐‐‐‐‐ 123 79 44 112 72 40 11 7 4 Melanoma of the Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 96 61 35 89 57 32 6 3 3 Other Non‐Epithelial Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 27 18 9 23 14 8 4 4 1

Table G1. Average Annual Number of Cancer Deaths, 2001‐2005, Louisiana

Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 733 9 724 457 6 451 272 3 269

Female Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 380 ‐‐ 380 242 ‐‐ 242 135 ‐‐ 135 Cervix Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 70 ‐‐ 70 32 ‐‐ 32 37 ‐‐ 37 Corpus and Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 87 ‐‐ 87 45 ‐‐ 45 42 ‐‐ 42 Corpus Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 34 ‐‐ 34 18 ‐‐ 18 15 ‐‐ 15 Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 54 ‐‐ 54 27 ‐‐ 27 27 ‐‐ 27 Ovary‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 205 ‐‐ 205 153 ‐‐ 153 50 ‐‐ 50 Vagina‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 6 ‐‐ 6 4 ‐‐ 4 2 ‐‐ 2 Vulva‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8 ‐‐ 8 5 ‐‐ 5 2 ‐‐ 2 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4 ‐‐ 4 3 ‐‐ 3 2 ‐‐ 2

Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 500 500 ‐‐ 290 290 ‐‐ 207 207 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 491 491 ‐‐ 284 284 ‐‐ 204 204 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 6 6 ‐‐ 5 5 ‐‐ 1 1 ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 3 ‐‐ 1 1 ‐‐ 1 1 ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0 0 ‐‐ 0 0 ‐‐ 0 0 ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 404 254 150 311 200 111 92 53 39 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 164 107 57 129 88 40 35 19 16 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 231 141 90 175 107 68 54 33 21 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3 2 1 2 1 1 1 1 0 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7 4 3 5 3 2 2 1 2

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4 2 2 4 2 2 0 0 0

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 201 112 89 159 89 71 40 23 18

Endocrine System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 41 16 25 28 12 16 12 3 9 Thyroid‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 24 8 16 17 7 10 7 1 6 Thymus and Other Endocrine‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 17 7 10 11 5 6 6 2 3

Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 354 183 171 285 149 136 66 33 34 Hodgkin Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 22 11 12 17 9 9 5 2 3 Non‐Hodgkin lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 331 172 160 268 141 128 61 31 31

Multiple Myeloma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 178 96 81 105 57 48 73 39 34

Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 317 176 141 235 131 104 80 45 36 Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 84 50 34 61 34 26 23 15 8 Acute Lymphocytic ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 18 10 8 11 6 5 6 4 2 Chronic Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 59 37 22 45 27 19 14 10 4 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7 3 4 4 2 2 3 2 2 Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 134 75 59 101 59 43 31 16 16 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 107 61 46 82 48 34 24 12 11 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1 0 1 1 0 1 0 0 0 Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 18 9 8 11 6 4 7 3 4 Other Myeloid/Monocytic Leukemia‐‐‐‐ 8 5 4 7 4 3 1 0 0 Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 99 51 48 73 38 36 26 13 12 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 27 12 15 23 10 13 4 2 2 Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 72 39 33 51 28 23 21 11 10

Ill‐Defined and Unknown Sites‐‐‐‐‐‐‐‐‐‐‐‐ 760 414 346 529 288 242 227 125 103


‐‐ Not applicable.


Total Males Females Total Males Females Total Males Females

All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.6 2.2 0.9 1.5 2.0 1.0 1.8 2.6 0.9 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.4 0.2 0.3 0.4 0.2 0.3 0.4 0.1 Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.2 0.2 0.3 0.1 0.3 0.4 0.2 Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.3 0.1 Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.8 0.2 0.5 0.7 0.2 0.7 1.1 0.3

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 23.8 24.8 22.7 22.8 24.0 21.3 26.0 26.2 25.9 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.0 3.0 0.9 2.0 3.1 0.9 2.0 3.0 1.0 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.3 2.6 1.9 1.6 1.9 1.3 3.7 4.0 3.2 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 10.1 9.9 10.3 9.7 9.9 9.6 10.8 9.9 12.0 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8.6 8.3 9.0 8.3 8.2 8.3 9.4 8.5 10.6 Rectum and Rectosigmoid Junction‐‐‐‐ 1.4 1.6 1.3 1.5 1.6 1.2 1.4 1.4 1.4 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 3.0 3.7 2.3 2.9 3.4 2.4 3.2 4.1 2.1 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.7 3.4 1.9 2.6 3.1 1.9 2.9 3.8 1.8 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.3 0.4 0.4 0.3 0.5 0.3 0.3 0.3 Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.2 0.4 0.3 0.2 0.4 0.3 0.2 0.5 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.4 4.9 6.1 5.5 5.1 5.9 5.4 4.5 6.5 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Peritoneum, Omentum and Mesentery‐‐‐‐‐ 0.1 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.1 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.2

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 31.4 35.8 26.2 32.7 36.1 28.7 28.5 35.2 20.6 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.8 1.3 0.4 0.7 1.0 0.3 1.2 1.8 0.4 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 30.4 34.4 25.8 31.8 34.9 28.3 27.3 33.3 20.2 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0



Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7.8 0.2 16.5 7.0 0.2 14.8 9.6 0.2 20.5

Table G2. Percent Distribution of Cancer Deaths, 2001‐2005, Louisiana


Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.3 9.9 ‐‐ 4.4 8.3 ‐‐ 7.3 13.5 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.2 9.7 ‐‐ 4.3 8.1 ‐‐ 7.2 13.3 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 ‐‐ 0.1 0.1 ‐‐ 0.0 0.1 ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.1 ‐‐ 0.0 0.0 ‐‐ 0.0 0.1 ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 ‐‐ 0.0 0.0 ‐‐ 0.0 0.0 ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.3 5.0 3.4 4.8 5.7 3.7 3.2 3.5 2.9 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.7 2.1 1.3 2.0 2.5 1.3 1.2 1.2 1.2 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.4 2.8 2.0 2.7 3.1 2.2 1.9 2.2 1.6 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.1 2.2 2.0 2.4 2.5 2.3 1.4 1.5 1.4




Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.4 3.5 3.2 3.6 3.7 3.4 2.8 2.9 2.7 Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.9 1.0 0.8 0.9 1.0 0.9 0.8 1.0 0.6 Acute Lymphocytic ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 Chronic Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.7 0.5 0.7 0.8 0.6 0.5 0.7 0.3 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 1.4 1.5 1.4 1.5 1.7 1.4 1.1 1.0 1.2 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.1 1.2 1.1 1.3 1.4 1.1 0.8 0.8 0.9 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.3 Other Myeloid/Monocytic Leukemia‐‐‐‐ 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.0 1.0 1.1 1.1 1.1 1.2 0.9 0.9 0.9 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.2 0.3 0.3 0.3 0.4 0.2 0.1 0.2 Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 0.8 0.8 0.7 0.8 0.8 0.8 0.7 0.7 0.7


‐‐ Not applicable.


Total Males Females Total Males Females Total Males Females All Sites Combined‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 221.0 285.9 178.0 206.2 262.8 168.2 269.3 370.1 207.0

Oral Cavity and Pharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.5 5.8 1.7 3.1 5.0 1.6 4.6 8.7 1.7 Lip‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ 0.0 0.0 0.0 Tongue‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 1.0 0.4 0.7 1.0 0.4 0.6 1.1 ^ Salivary Gland‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.4 0.2 0.3 0.4 ^ ^ ^ ^ Floor of Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ 0.0 ^ ^ 0.0 0.0 0.0 0.0 Gum and Other Mouth‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.5 0.8 0.3 0.4 0.7 0.2 0.8 1.3 ^ Nasopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 0.2 0.2 0.3 ^ 0.3 ^ ^ Tonsil‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.3 ^ 0.2 0.3 ^ ^ ^ ^ Oropharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.5 0.2 0.3 0.4 ^ 0.5 0.8 ^ Hypopharynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.2 ^ 0.1 ^ ^ ^ ^ ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.2 2.2 0.4 1.0 1.7 0.4 1.9 3.8 0.5

Digestive System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 52.7 69.8 39.9 46.9 62.5 35.0 71.1 95.2 54.7 Esophagus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.4 8.1 1.6 4.2 7.6 1.5 5.4 9.9 2.1 Stomach‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.0 7.4 3.4 3.4 4.9 2.2 10.2 15.5 6.9 Small Intestine‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.3 0.4 0.3 0.3 0.3 0.4 0.4 ^ ^ Colon and Rectum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 22.3 28.5 17.9 20.0 26.2 15.6 29.8 36.9 25.1 Colon ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 19.1 24.1 15.7 17.0 21.9 13.5 26.1 32.0 22.3 Rectum and Rectosigmoid Junction‐‐‐‐ 3.2 4.4 2.2 3.0 4.2 2.1 3.7 4.9 2.9 Anus, Anal Canal and Anorectum‐‐‐‐‐‐‐‐‐ 0.1 ^ 0.2 0.1 ^ ^ ^ ^ ^ Liver and Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐ 6.7 10.0 4.1 6.1 8.8 3.9 8.2 13.5 4.4 Liver‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.9 9.2 3.4 5.3 8.0 3.2 7.4 12.5 3.8 Intrahepatic Bile Duct‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.8 0.8 0.7 0.8 0.8 0.8 0.8 1.0 0.6 Gallbladder‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.7 0.6 0.7 0.6 0.5 0.6 0.9 ^ 0.9 Other Biliary Tract‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.4 0.4 0.4 0.3 0.5 ^ ^ Pancreas‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12.1 13.8 10.7 11.3 13.1 9.7 15.1 16.6 13.8 Retroperitoneum‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ ^ 0.0 ^ Peritoneum, Omentum and Mesentery‐‐‐‐‐ 0.2 ^ 0.3 0.2 ^ 0.3 ^ ^ ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.3 0.3 0.4 0.2 0.5 ^ ^

Respiratory System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 69.1 99.7 47.1 67.0 92.4 48.6 76.3 126.1 43.2 Nose, Nasal Cavity and Middle Ear‐‐‐‐‐‐ 0.1 ^ ^ 0.1 ^ ^ ^ ^ 0.0 Larynx‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.8 3.4 0.6 1.5 2.6 0.6 3.0 6.2 0.8 Lung and Bronchus‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 67.0 95.9 46.3 65.3 89.4 47.8 73.1 119.4 42.4 Pleura‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ ^ ^ 0.0 Trachea and Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ ^ ^ 0.0


Skin (Excl. basal and squamous)‐‐‐‐‐‐‐‐‐‐‐ 2.9 4.4 1.8 3.6 5.3 2.2 1.0 1.7 0.6 Melanoma of the Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.2 3.3 1.4 2.8 4.1 1.8 0.6 0.9 ^ Other Non‐Epithelial Skin‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 1.1 0.3 0.7 1.2 0.4 0.4 0.7 ^

Table H. Average Annual Cancer Mortality Rates,1 2001‐2005, Louisiana

Breast‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 17.0 0.5 29.7 14.4 0.4 25.3 24.2 ^ 40.9

Female Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8.9 ‐‐ 15.6 7.7 ‐‐ 13.6 12.7 ‐‐ 21.3 Cervix Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.6 ‐‐ 3.0 1.1 ‐‐ 2.0 3.1 ‐‐ 5.5 Corpus and Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.1 ‐‐ 3.6 1.4 ‐‐ 2.5 4.2 ‐‐ 6.9 Corpus Uteri‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.8 ‐‐ 1.4 0.6 ‐‐ 1.0 1.5 ‐‐ 2.5 Uterus, NOS‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.3 ‐‐ 2.2 0.8 ‐‐ 1.5 2.7 ‐‐ 4.4 Ovary‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.8 ‐‐ 8.3 4.8 ‐‐ 8.5 4.8 ‐‐ 8.0 Vagina‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ‐‐ 0.2 0.1 ‐‐ 0.2 ^ ‐‐ ^ Vulva‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 ‐‐ 0.3 0.2 ‐‐ 0.3 ^ ‐‐ ^ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ‐‐ 0.2 ^ ‐‐ ^ ^ ‐‐ ^

Male Genital System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 12.1 32.7 ‐‐ 9.2 25.0 ‐‐ 21.8 60.7 ‐‐ Prostate‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 11.9 32.2 ‐‐ 9.0 24.5 ‐‐ 21.5 60.0 ‐‐ Testis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 0.3 ‐‐ 0.2 0.3 ‐‐ ^ ^ ‐‐ Penis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ‐‐ ^ ^ ‐‐ ^ ^ ‐‐ Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ‐‐ ^ ^ ‐‐ ^ ^ ‐‐

Urinary System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 9.5 14.6 6.0 9.8 15.2 6.0 8.8 12.9 6.2 Urinary Bladder (Incl. In Situ)‐‐‐‐‐‐‐‐‐‐‐‐‐ 3.9 6.7 2.2 4.1 7.2 2.1 3.5 5.1 2.6 Kidney and Renal Pelvis‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 5.4 7.6 3.6 5.5 7.7 3.8 5.0 7.4 3.3 Ureter‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ ^ ^ 0.0 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.1 0.2 ^ ^ ^ ^ ^

Eye and Orbit‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.1 ^ ^ 0.1 ^ ^ 0.0 0.0 0.0

Brain and Nervous System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 4.6 5.9 3.7 5.1 6.4 4.1 3.4 4.5 2.6

Endocrine System‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.9 0.8 1.0 0.9 0.9 0.9 1.1 0.6 1.4 Thyroid‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.4 0.6 0.5 0.5 0.6 0.7 ^ 0.9 Thymus and Other Endocrine‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.3 0.4 0.4 0.4 0.4 0.4 ^ 0.5

Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 8.3 10.4 6.9 9.0 11.4 7.4 6.1 7.2 5.3 Hodgkin Lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.5 0.6 0.5 0.6 0.7 0.5 0.4 ^ ^ Non‐Hodgkin lymphoma‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7.8 9.8 6.4 8.5 10.8 6.9 5.7 6.8 4.9


Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 7.5 10.1 5.7 7.5 10.0 5.7 7.5 10.5 5.5 Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.0 2.9 1.4 1.9 2.6 1.4 2.2 3.7 1.3 Acute Lymphocytic ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.3 0.4 0.4 0.3 0.5 0.7 ^ Chronic Lymphocytic‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 1.4 2.2 0.9 1.4 2.1 1.0 1.4 2.6 0.6 Other‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.2 0.2 0.2 0.1 ‐‐ ‐‐ 0.3 ^ ^ Myeloid and Monocytic Leukemia‐‐‐‐‐‐‐‐ 3.1 4.2 2.4 3.2 4.4 2.4 2.8 3.4 2.4 Acute Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.5 3.4 1.9 2.6 3.6 2.0 2.1 2.8 1.7 Acute Monocytic Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ ^ ^ ^ ^ ^ ^ ^ 0.0 ^ Chronic Myeloid Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.4 0.5 0.3 0.3 0.5 0.3 0.6 ^ 0.5 Other Myeloid/Monocytic Leukemia‐‐‐‐ 0.2 0.3 0.1 0.2 0.3 0.2 ^ ^ ^ Other Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 2.4 3.1 1.9 2.3 3.0 1.9 2.5 3.4 1.9 Other Acute Leukemia‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 0.6 0.7 0.6 0.7 0.8 0.7 0.4 ^ ^ Aleukemic, Subleukemic and NOS‐‐‐‐‐‐ 1.7 2.4 1.3 1.6 2.2 1.2 2.1 2.9 1.5


1. Average annual rate per 100,000, age adjusted to the U.S. 2000 standard

^ Rates are not generated for cells with counts less than 16. ‐‐ Not applicable

Primary Site

U.S. La.Ind.

Corr.U.S. La.

Ind.

Corr.U.S. La.

Ind.

Corr.U.S. La.

Ind.

Corr.

All Sites Combined 230.7 262.8 ↑ 234.7 * 159.2 168.2 ↑ 157.3 * 313.0 370.1 ↑ 345.1 * 186.7 207.0 ↑ 200.1

Oral Cavity and Pharynx 3.8 5.0 ↑ 2.9 * 1.5 1.6 1.4 6.7 8.7 ↑ 6.2 1.6 1.7 ^

Esophagus 7.8 7.6 8.1 1.6 1.5 ^ 9.8 9.9 9.1 2.8 2.1 ↓ ^

Stomach 5.0 4.9 4.1 2.5 2.2 ↓ 2.0 11.5 15.5 ↑ 14.8 5.5 6.9 ↑ 7.8

Colon 18.3 21.9 ↑ 16.9 * 13.1 13.5 13.3 27.1 32.0 ↑ 27.2 19.7 22.3 ↑ 19.5

Rectum 3.8 4.2 2.8 2.2 2.1 1.8 4.5 4.9 ^ 2.6 2.9 ^

Pancreas 12.1 13.1 ↑ 10.3 * 9.0 9.7 ↑ 10.5 15.4 16.6 13.9 12.4 13.8 ↑ 14.2

Larynx 2.1 ^ ↑ ^ 0.5 0.6 ^ 4.8 6.2 ↑ ^ 0.8 0.8 ^

Lung and Bronchus 71.3 89.4 ↑ 75.8 * 42.0 47.8 ↑ 40.7 * 93.1 119.4 ↑ 110.9 39.9 42.4 ↑ 35.5 *

Breast 0.3 0.4 ^ 24.4 25.3 23.7 0.5 ^ 0.0 33.5 40.9 ↑ 42.0

Cervix Uteri ‐‐ ‐‐ ‐‐ 2.3 2.0 ^ ‐‐ ‐‐ ‐‐ 4.7 5.5 ↑ 3.0 *

Uterus and Corpus ‐‐ ‐‐ ‐‐ 3.9 2.5 ↓ 2.3 ‐‐ ‐‐ ‐‐ 7.1 6.9 6.1

Ovary ‐‐ ‐‐ ‐‐ 9.2 8.5 8.5 ‐‐ ‐‐ ‐‐ 7.5 8.0 9.3

Prostate 24.6 24.5 22.4 ‐‐ ‐‐ ‐‐ 59.4 60.0 54.8 ‐‐ ‐‐ ‐‐

Testis 0.3 0.3 ^ ‐‐ ‐‐ ‐‐ 0.2 ^ ^ ‐‐ ‐‐ ‐‐

Urinary Bladder 7.9 7.2 6.9 2.2 2.1 2.1 5.4 5.1 ^ 2.8 2.6 ^

Kidney and Renal Pelvis 6.2 7.7 ↑ 6.0 2.8 3.8 ↑ 3.2 6.1 7.4 ↑ 6.4 2.7 3.3 ^

Brain and Other Nervous System 5.7 6.4 ↑ 7.0 3.9 4.1 4.9 3.2 4.5 ↑ ^ 2.1 2.6 ↑ 4.4

Hodgkin Lymphoma 0.6 0.7 ^ 0.4 0.5 ^ 0.5 ^ ^ 0.3 ^ ^

Non‐Hodgkin Lymphoma 9.7 10.8 ↑ 7.9 * 6.2 6.9 ↑ 5.7 6.4 6.8 7.3 4.2 4.9 4.1

Multiple Myeloma 4.3 4.3 3.9 2.8 2.6 2.6 8.3 9.9 ↑ 11.1 6.0 5.5 6.0

Leukemia 10.2 10.0 10.5 5.7 5.7 5.4 8.5 10.5 ↑ 8.9 5.2 5.5 5.2

1. Rates per 100,000, age adjusted to the U.S. 2000 standard

2. The Industrial Corridor comprises Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes.


^ Rates are not calculated if fewer than 16 deaths occur in the five‐year period.

↑ or ↓ The Louisiana rate is significantly higher or lower (p < 0.05) than the U.S. rate.



Table I. Average Annual Cancer Mortality Rates,1 2001‐2005: U.S., Louisiana, Industrial Corridor2

White Males White Females Black Males Black Females


U.S. Louisiana Orleans Rouge east west west east


All Sites Combined 230.7 262.8 ↑ 265.5 246.4 * 269.0 269.5 271.4 270.9 264.2 256.1

Lung 71.3 89.4 ↑ 83.1 * 82.1 * 91.8 89.9 98.9 # 99.2 # 92.3 93.7

Colon and rectum 22.1 26.2 ↑ 25.1 24.0 28.6 29.6 25.3 26.9 28.3 21.2 *

Prostate 24.6 24.5 25.0 22.7 24.9 26.9 24.4 24.1 22.5 26.1

Pancreas 12.1 13.1 ↑ 14.2 12.2 10.5 * 14.3 13.4 15.9 12.9 12.8

Non‐Hodgkin lymphoma 9.7 10.8 ↑ 11.1 9.8 11.5 12.1 11.4 9.0 9.4 12.0

Leukemia 10.2 10.0 9.9 9.7 9.6 9.7 7.6 11.9 11.5 10.9

Liver 5.4 8.0 ↑ 10.6 # 7.6 9.4 6.6 11.1 # 6.3 5.0 * 6.1

Kidney 6.2 7.7 ↑ 8.4 6.9 7.3 7.0 10.1 7.8 7.6 7.6

Esophagus 7.8 7.6 8.5 7.0 8.4 6.9 7.0 7.1 7.9 7.4

Bladder 7.9 7.2 8.9 6.6 6.2 8.3 6.7 5.6 6.4 6.8

1. Average annual rates per 100,000, age‐adjusted to the U.S. 2000 standard. See "Calculating 2005 Rates" in the Introduction.

↑ or ↓ The Louisiana rate is significantly higher or lower (p < 0.05) than the U.S. rate.



See page ___ for a list of parishes in each LTR region.

Table J1. Ten Most Common Causes of Cancer Death,1 2001‐2005: White Males

U.S., Louisiana, and Louisiana Tumor Registry Regions


Region

Central

Region

Primary Site New Baton South‐ South‐ North‐ North‐


Region Region Region Region Region

All Sites 159.2 168.2 ↑ 172.2 161.8 164.3 177.4 # 181.8 # 169.0 161.5 160.6

Lung 42.0 47.8 ↑ 48.9 42.4 * 46.3 52.9 # 50.5 46.6 49.1 47.3

Breast 24.4 25.3 28.0 24.9 24.6 25.8 26.1 25.6 21.3 * 26.0

Colon and rectum 15.3 15.6 14.8 16.4 15.5 15.4 17.8 17.9 15.6 12.6 *

Pancreas 9.0 9.7 ↑ 8.5 9.9 9.8 13.8 # 8.5 11.0 8.2 8.2

Ovary 9.2 8.5 ↓ 9.8 8.6 7.2 7.6 7.8 7.5 9.1 9.5

Non‐Hodgkin lymphoma 6.2 6.9 ↑ 7.2 6.6 6.4 7.8 9.0 6.8 6.0 5.8

Leukemia 5.7 5.7 6.4 6.1 6.3 4.5 5.5 4.7 5.2 5.8

Brain and CNS 3.9 4.1 4.0 4.7 3.3 3.0 5.8 5.8 3.6 4.6

Kidney 2.8 3.8 ↑ 3.5 3.3 3.6 5.3 4.8 4.0 3.1 3.2

Liver 1.9 3.2 ↑ 3.6 3.2 2.5 2.1 * 5.3 # 3.1 2.9 3.6






Table J2. Ten Most Common Causes of Cancer Death,1 2001‐2005: White Females


Acadiana

Region

Central

Region


U.S Louisiana Orleans Rouge east west west east


All Sites Combined 313.0 370.1 ↑ 391.0 # 359.1 367.0 361.6 340.4 345.5 375.4 366.5

Lung and Bronchus 93.1 119.4 ↑ 125.4 114.8 130.5 120.8 115.0 114.9 111.7 117.1

Prostate 59.4 60.0 61.0 59.8 55.3 42.3 * 45.2 59.5 64.5 83.4 #

Colon and Rectum 31.8 36.9 ↑ 43.7 # 31.5 44.7 28.7 * 28.9 33.9 40.9 31.7

Pancreas 15.4 16.6 13.8 15.9 16.0 25.1 * 11.1 16.4 19.8 15.0

Stomach 11.5 15.5 ↑ 17.8 13.7 14.7 16.8 17.8 12.4 15.1 14.5

Liver 9.1 12.5 ↑ 16.5 # 13.4 8.2 11.2 12.6 7.4 11.9 7.3 *

Leukemia 8.5 10.5 ↑ 12.5 9.5 7.4 10.7 7.0 10.7 10.6 10.2

Esophagus 9.8 9.9 7.5 9.5 11.6 11.8 11.0 6.7 13.4 9.6

Multiple Myeloma 8.3 9.9 ↑ 11.9 9.1 7.3 7.8 4.5 10.1 10.8 11.1

Oral cavity 6.7 8.7 ↑ 7.6 7.1 8.8 11.5 15.5 5.5 9.0 9.8






Primary Site

Table J3. Ten Most Common Causes of Cancer Death,1 2001‐2005: Black Males


Acadiana

Region

Central

Region

Primary Site New Baton South‐ South‐ North‐ North‐



All Sites Combined 186.8 207.0 ↑ 220.7 # 198.3 208.1 205.4 222.4 207.8 192.7 * 206.4

Lung 39.9 42.4 ↑ 47.7 # 37.0 43.0 45.1 52.6 51.8 34.3 * 37.5

Breast 33.5 40.9 ↑ 43.5 39.8 39.6 37.4 41.4 32.8 40.6 46.1

Colon and Rectum 22.4 25.1 ↑ 28.5 22.6 24.1 25.2 33.6 25.5 24.1 19.7

Pancreas 12.4 13.8 ↑ 14.6 13.9 11.8 16.4 20.4 9.1 12.1 12.6

Ovary 7.5 8.0 7.3 9.0 8.1 8.0 7.1 8.0 8.1 9.2

Stomach 5.5 6.9 ↑ 6.4 7.5 11.1 # 7.6 2.4 9.8 5.6 5.9

Uterus and Corpus 7.1 6.9 6.6 7.5 9.0 4.9 5.3 5.1 7.1 8.9

Cervix 4.7 5.5 ↑ 4.2 2.9 * 5.3 5.6 3.5 8.3 9.5 # 7.6

Leukemia 5.2 5.5 5.8 5.2 6.3 6.3 5.5 6.5 4.3 5.7

Multiple Myeloma 6.0 5.5 4.8 5.5 6.7 6.0 8.0 4.8 5.0 6.3






Table J4. Ten Most Common Causes of Cancer Death,1 2001‐2005: Black Females


Acadiana

Region

Central

Region




All Malignant Cancers 230.7 262.8 ↑ 266.5 232.8 * 266.7 272.2 271.4 270.9 264.2 256.1 268.9

Lung and Bronchus 71.3 89.4 ↑ 84.0 74.4 * 91.7 89.8 98.9 # 99.2 # 92.3 93.7 93.5

Colon and rectum 22.1 26.2 ↑ 25.6 21.4 * 28.1 30.2 # 25.3 26.9 28.3 21.2 * 28.0

Prostate 24.6 24.5 25.0 22.0 24.0 26.6 24.4 24.1 22.5 26.1 25.8

Pancreas 12.1 13.1 ↑ 14.2 11.3 10.4 14.7 13.4 15.9 12.9 12.8 12.0

Non‐Hodgkin Lymphoma 9.7 10.8 ↑ 11.1 8.4 12.1 12.0 11.4 9.0 9.4 12.0 11.8

Leukemia 10.2 10.0 9.9 9.8 8.6 9.8 7.6 11.9 11.5 10.9 10.3

Liver 5.4 8.0 ↑ 10.4 # 7.4 8.0 6.7 11.1 # 6.3 5.0 * 6.1 9.6

Kidney and Renal Pelvis 6.2 7.7 ↑ 8.3 6.1 7.5 7.4 10.1 7.8 7.6 7.6 7.4

Esophagus 7.8 7.6 8.6 7.0 6.5 7.0 7.0 7.1 7.9 7.4 8.6

Urinary Bladder 7.9 7.2 9.0 # 6.2 4.7 * 8.4 6.7 5.6 6.4 6.8 8.0






Table K1. Ten Most Common Causes of Cancer Deaths,1 2001‐2005: White Males

U.S., Louisiana, and Louisiana Office of Public Health Regions2

Primary SiteCentral

Region

North‐

lake

Region

Acadiana

Region




All Malignant Cancers 159.2 168.2 ↑ 173.0 155.8 * 156.0 * 178.2 # 181.8 # 169.0 161.5 160.6 174.1

Lung and Bronchus 42.0 47.8 ↑ 48.9 39.9 * 41.1 * 52.8 # 50.5 46.6 49.1 47.3 51.6

Breast 24.4 25.3 27.9 24.4 23.6 26.2 26.1 25.6 21.3 * 26.0 25.6

Colon and rectum 15.3 15.6 15.1 14.7 14.0 15.5 17.8 17.9 15.6 12.6 * 18.4 #Pancreas 9.0 9.7 ↑ 8.7 9.8 10.3 13.6 # 8.5 11.0 8.2 8.2 9.8

Ovary 9.2 8.5 ↓ 9.7 9.3 6.6 8.0 7.8 7.5 9.1 9.5 7.5

Non‐Hodgkin Lymphoma 6.2 6.9 ↑ 7.2 5.9 6.7 7.7 9.0 6.8 6.0 5.8 6.8

Leukemia 5.7 5.7 6.5 6.0 5.5 4.5 5.5 4.7 5.2 5.8 6.5

Brain 3.9 4.1 3.9 5.1 3.8 2.8 * 5.8 5.8 3.6 4.6 3.7

Kidney and Renal Pelvis 2.8 3.8 ↑ 3.6 2.7 4.4 5.2 # 4.8 4.0 3.1 3.2 3.4

Liver 1.9 3.2 ↑ 3.8 3.0 3.0 2.0 * 5.3 # 3.1 2.9 3.6 2.4






Table K2. Ten Most Common Causes of Cancer Deaths,1 2001‐2005: White Females


Primary SiteCentral

Region

North‐

lake

Region

Acadiana

Region



Region Region Region Region Region Region Region

All Malignant Cancers 313.0 370.1 ↑ 390.3 # 354.1 373.8 365.0 340.4 345.5 375.4 366.5 363.8

Lung and Bronchus 93.1 119.4 ↑ 125.4 115.3 124.2 125.1 115.0 114.9 111.7 117.1 117.6

Prostate 59.4 60.0 60.6 59.6 56.4 42.0 * 45.2 59.5 64.5 83.4 # 57.0

Colon and rectum 31.8 36.9 ↑ 43.8 # 31.7 34.4 28.1 * 28.9 33.9 40.9 31.7 45.0

Pancreas 15.4 16.6 14.0 15.0 16.8 25.7 # 11.1 16.4 19.8 15.0 17.9

Stomach 11.5 15.5 ↑ 17.7 12.1 22.3 17.0 17.8 12.4 15.1 14.5 10.8

Liver 9.1 12.5 ↑ 16.3 # 13.4 8.5 11.7 12.6 7.4 11.9 7.3 * 10.5

Leukemia 8.5 10.5 ↑ 12.3 8.6 9.1 10.8 7.0 10.7 10.6 10.2 10.1

Esophagus 9.8 9.9 7.4 8.7 15.2 12.1 11.0 6.7 13.4 9.6 8.6

Multiple Myeloma 8.3 9.9 ↑ 11.7 9.9 9.4 7.8 4.5 10.1 10.8 11.1 4.3

Oral cavity 6.7 8.7 ↑ 7.8 6.9 7.8 11.9 15.5 5.5 9.0 9.8 8.3






Table K3. Ten Most Common Causes of Cancer Deaths,1 2001‐2005: Black Males


Primary SiteAcadiana Central

Region

North‐

lake

Region




All Malignant Cancers 186.7 207.0 ↑ 220.7 # 194.8 225.7 204.6 222.4 207.8 192.7 * 206.4 192.8

Lung and Bronchus 39.9 42.4 ↑ 47.1 34.0 * 42.8 47.4 52.6 51.8 34.3 * 37.5 46.8

Breast 33.5 40.9 ↑ 43.8 40.0 41.8 37.6 41.4 32.8 40.6 46.1 32.9

Colon and rectum 22.4 25.1 ↑ 28.6 21.1 29.2 23.8 33.6 25.5 24.1 19.7 24.4

Pancreas 12.4 13.8 ↑ 14.6 14.7 10.5 17.3 20.4 9.1 12.1 12.6 11.3

Ovary 7.5 8.0 7.4 9.3 9.9 7.6 7.1 8.0 8.1 9.2 6.0

Stomach 5.5 6.9 ↑ 6.3 7.0 14.7 # 6.5 2.4 9.8 5.6 5.9 8.1

Uterus and corpus 7.1 6.9 6.6 6.4 7.8 5.1 5.3 5.1 7.1 8.9 11.4

Cervix Uteri 4.7 5.5 ↑ 4.1 2.7 * 4.4 5.9 3.5 8.3 9.5 # 7.6 5.4

Leukemia 5.2 5.5 5.9 5.0 5.6 6.6 5.5 6.5 4.3 5.7 6.1

Myeloma 6.0 5.5 5.1 5.2 7.3 5.3 8.0 4.8 5.0 6.3 6.0



* The age‐adjusted rate is significantly different (p<0.05) from the U.S. rate.



Table K4. Ten Most Common Causes of Cancer Deaths,1 2001‐2005: Black Females

North‐

lake

Region


Primary SiteCentral

Region

Acadiana

Region

Appendices

Appendix 1 Cancer in Louisiana Monograph Series

Correa P, Chen VW, Craig JF, Ballinger T, Campbell W, Zavala DE. Cancer in Louisiana,[vol. 1]. Baton Rouge: Division of Administration, 1983.

Correa P, Chen VW, Craig, JF, Zavala DE. Cancer in Louisiana, vol. 2. Baton Rouge: Louisiana Division of

Administration, 1985. Correa P, Chen VW, Craig JF, Groves FD. Cancer in Louisiana, vol. 3. Baton Rouge: Louisiana Division of

Administration, [1986]. Chen VW, Craig JF, Correa P, Groves FD, Ballinger TE, Zavala DE. Cancer in Louisiana, vol. 4. Baton

Rouge: LSU Graphic Services, 1987. Groves FD, Craig JF, Correa P, Chen VW, Fontham ETH, Zavala DE. Cancer in Louisiana, vol. 5. Baton Rouge: LSU Graphic Services, 1989. Chen VW, Craig JF, Fontham E, Lin Y, Correa P. Cancer Incidence in South Louisiana, 1983–1986. Baton

Rouge: LSU Graphic Services, 1990. (Cancer in Louisiana; vol. 6.) Chen VW, Fontham E, Groves FD, Craig JF, Correa P. Cancer Incidence in South Louisiana, 1983–1986.

New Orleans: Epidemiology Section, Louisiana State University Medical Center, and Louisiana Tumor Registry, 1991. (Cancer in Louisiana; vol. 7.)

Chen VW, Correa CN, Wu XC, et al. Cancer Incidence in Louisiana, 1988–1992. New Orleans:

Louisiana Tumor Registry, 1996. 9 volumes. (Cancer in Louisiana, vol. 8; nos. 1–9.) Wu XC, Correa CN, Andrews PA, Li F, Joy JA, Chen VW. Cancer Incidence and Mortality in Loui-siana,

1989–1993. New Orleans: Louisiana Tumor Registry, 1998. (Cancer in Louisiana; vol. 9.) Andrews PA, Correa CN, Wu XC, Li F, Schmidt BA, Chen VW. Cancer Incidence and Mortality in

Louisiana, 1990–1994. New Orleans: Louisiana Tumor Registry, 1998. (Cancer in Louisiana; vol. 10.)

Andrews PA, Wu XC, Correa CN, Schmidt BA, Ahmed MN, Chen VW. Cancer Incidence and

Mortality in Louisiana, 1991–1995. New Orleans: Louisiana Tumor Registry, 2000. (Cancer in Louisiana; vol. 11.)

Correa CN, Wu XC, Andrews PA, Ahmed MN, Schmidt BA, Chen VW. Cancer Incidence and


Wu XC, Correa CN, Andrews PA, Hsieh MC, Schmidt BA, Ahmed MN. Chen VW. Cancer Incidence and


Chen VW, Schmidt BA, Wu XC, Correa CN, Andrews PA, Hsieh MC, Ahmed MN. Childhood Cancer in

Louisiana, 1988–1996. New Orleans: Louisiana Tumor Registry, 2001. (Cancer in Louisiana; vol. 14). Available at http://publichealth.lsuhsc.edu/tumorregistry/PDF/Childhood_Cancer.pdf

Andrews PA, Correa CN, Wu XC, Hsieh MC, Schmidt BA, Chen VW. Cancer Incidence and Mortality in

Louisiana, 1994–1998. New Orleans: Louisiana Tumor Registry, 2002. (Cancer in Louisiana; vol. 15.)

Correa CN, Wu XC, Andrews PA, Hsieh MC, Chen VW. Cancer Incidence and Mortality in Louisiana,

1995–1999. New Orleans: Louisiana Tumor Registry, 2003. (Cancer in Louisiana; vol. 16.) Correa CN, Wu XC, Andrews PA, Hsieh MC, Chen VW. Cancer Incidence and Mortality in Louisiana,

1996–2000. New Orleans: Louisiana Tumor Registry, 2003. (Cancer in Louisiana; vol. 17.) Available at http://publichealth.lsuhsc.edu/tumorregistry/statistics_monographs_LCR2000.asp

Correa CN, Wu XC, Andrews PA, Hsieh MC, Chen VW. Parish Profiles, 1988–2000. New Orleans:

Louisiana Tumor Registry, 2003. (Cancer in Louisiana; vol. 18.) Available at: http://publichealth.lsuhsc.edu/tumorregistry/statistics_parishes.asp

Hsieh MC, Andrews PA, Wu XC, Correa CN, Huang S, Chen L, Lucas HF, Chen VW. Cancer Incidence

and Mortality in Louisiana, 1997−2001. New Orleans: Louisiana Tumor Registry, 2005. (Cancer in Louisiana; vol. 19.) Available at http://publichealth.lsuhsc.edu/tumorregistry/PDF/MONOGRAPH%201997-2001.pdf

Hsieh M-C, Andrews PA, Correa CN, Wu X, Chen L, Huang S, Lucas HF, Chen VW. Cancer in Louisiana,

1998-2002. New Orleans: Louisiana Tumor Registry, 2005. (Cancer in Louisiana; vol. 20.) Available only in electronic format, at http://publichealth.lsuhsc.edu/tumorregistry/PDF/Cancer_Incidence_Mortality_Vol20.pdf.

Hsieh M, Andrews PA, Wu X, Chen L, Huang S, Peters ES, Chen VW. Cancer in Louisiana, 1999-2003.

New Orleans: Louisiana Tumor Registry, 2006. Cancer in Louisiana; vol. 21.) Available at http://publichealth.lsuhsc.edu/tumorregistry/PDF/Cancer_Incidence_Mortality_Vol21.pdf.

Peters ES, Schmidt BA, Andrews, PA, Hsieh M, Mumphrey B, Wu X, Chen VW. Cancer in Louisiana,

2000-2004. New Orleans: Louisiana Tumor Registry, 2007. (Cancer in Louisiana, vol. 22.) Available at http://publichealth.lsuhsc.edu/tumorregistry/PDF/LTRVol22.pdf.

.

Appendix 2

Louisiana Tumor Registry

Addresses and Phone Numbers

Central Office Louisiana Tumor Registry 1615 Poydras Street, Suite 1400 New Orleans, LA 70112 Phone: (504) 568-5757 Fax: (504) 568-5800 E-mail: [email protected] Regions 1 and 3 New Orleans and Southeast Louisiana Regional Tumor Registry 1615 Poydras Street, Suite 1400 New Orleans, LA 70112 Phone: (504) 568-5757 Fax: (504) 568-5800 Region 2 Baton Rouge Regional Tumor Registry 4950 Essen Lane Baton Rouge, LA 70809 Phone: (225) 767-0430 Fax: (225) 767-4742 Region 4 Acadiana Tumor Registry 1204 Johnston Street Lafayette, LA 70503 Phone: (337) 237-5398 Fax: (337) 235-9436

Region 5 Southwest Louisiana Regional Cancer Registry Christus−St. Patrick Hospital of Lake Charles 524 South Ryan Street Lake Charles, LA 70601 Phone: (337) 491-7790 Fax: (337) 430-5471 Regions 6, 7, and 8 North Louisiana Regional Tumor Registry (Includes Central, Northwest, and Northeast Louisiana) CNSB Room 221/226 University of Louisiana at Monroe 700 University Avenue Monroe, LA 71209-6604 Phone: (800) 423-8192 Fax: (318) 342-1824

Appendix 3

SEER Primary Site Recodes for Incidence (ICD-O-3)

Primary Site Site (C) Codes Morphology (M) Codes

Oral cavity and pharynx Lip C000-C009 Tongue C019-C029 Salivary gland C079-C089 Floor of mouth C040-C049 Gum and other mouth C030-C039, C050-C059, C060-C069 Nasopharynx C110-C119 Tonsil C090-C099 Oropharynx C100-C109 Hypopharynx C129, C130-C139 Other oral cavity and pharynx C140, C142-C148

Digestive system Esophagus C150-C159 Stomach C160-C169 Small intestine C170-C179 Colon Cecum C180 Appendix C181 Ascending colon C182 Hepatic flexure C183 Transverse colon C184 Splenic flexure C185 Descending colon C186 Sigmoid colon C187 Large intestine, NOS C188-C189, C260 Rectum Rectosigmoid junction C199 Rectum C209 Anus, anal canal, anorectum C210-C212, C218 Liver and intrahepatic bile duct Liver C220 Intrahepatic bile duct C221 Gallbladder C239 Other biliary C240-C249 Pancreas C250-C259 Retroperitoneum C480 Peritoneum, omentum, mesentery C481-C482 Other digestive organs C268-C269, C488

Respiratory system Nasal cavity, middle ear, and accessory sinuses C300-C301, C310-C319 Larynx C320-C329 Lung and bronchus C340-C349 Pleura C384 Trachea, Mediastinum, and C339, C381-C383, C388, C390, other respiratory organs C398, C399

Exclude 9590-9989; sometimes 9050-9055, 9140



Appendix 3 (page 2)



Bones and joints C400-C419Exclude 9590-9989; sometimes 9050-9055, 9140

Soft tissue (including heart) C380, C470-C479, C490-C499Exclude 9590-9989; sometimes 9050-9055, 9140

Skin (excluding basal cell and squamous cell) Melanoma of the skin C440-C449 8720-8790

Other, non-epithelial C440-C449 Exclude 8000-8005, 8010-8045, 8050- 8084, 8090-8110, 8720-8790, 9590-9989

and sometimes 9050-9055, 9140

Breast C500-C509Exclude 9590-9989; sometimes 9050-9055, 9140

Female genital system Cervix C530-C539 Corpus and Uterus, NOS Corpus uteri C540-C549 Uterus, NOS C559 Ovary C569 Vagina C529 Vulva C510-C519 Other female genital organs C570-C589

Male genital system Prostate C619 Testis C620-C629 Penis C600-C609 Other male genital organs C630-C639

Urinary system Bladder (including in situ) C670-C679 Kidney and renal pelvis C649, C659 Ureter C669 Other urinary organs C680-C689

Eye and Orbit C690-C699Exclude 9590-9989; sometimes 9050-9055, 9140

Brain and Other Nervous System

Brain C710-C719Exclude 9590-9989; sometimes 9050-9055, 9140

C710-C719 9530-9539

C700-C709, C720-C729Exclude 9590-9989; sometimes 9050-9055, 9140

Encodrine system Thyroid C739 Other endocrine (including C379, C740-C749, C750-C759 thymus)



Cranial Nerves and other nervous system



Appendix 3 (page 3)



Lymphoma Hodgkin lymphoma Nodal C024, C098-C099, C111, C142,

C379, C422, C770-C779 Extranodal All other sites

Non-Hodgkin lymphoma

NodalC024, C098-C099, C111, C142, C379, C422, C770-C779

9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9714-9719, 9727-9729, 9823, 9827

ExtranodalAll sites except C024, C098-C099, C111, C142, C379, C422, C770-C779

9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9714-9719, 9727-9729, 9823, 9827

Myeloma 9731-9732, 9734

Leukemia Lymphocytic Acute lymphocytic 9826, 9835-9837 Chronic lymphocytic 9823 Other lymphocytic 9820, 9832-9834, 9940 Myeloid and Monocytic Acute myeloid 9840, 9861, 9866, 9867, 9871-9874, 9895-9897, 9910, 9920 Acute monocytic 9891 Chronic myeloid 9863, 9875, 9876, 9945, 9946 Other myeloid/monocytic 9860, 9930 Other Leukemia Other acute 9801, 9805, 9931 Aleukemic, subleukemic, 9733, 9742, 9800, 9831, 9870, 9948, and NOS 9963, 9964, 9827

Mesothelioma 9050-9055

Kaposi sarcoma 9140

Ill-defined and unspecified sites 9740-9741, 9750-9758, 9760-9769, 9950, 9960-9962, 9970, 9975, 9980, 9982-9987, 9989

C420-C424, C760-C768, C770-C779, C809


Source: http://seer.cancer.gov/csr/1975_2005/results_merged/topic_siterecode.pdf

C420-C421, C424

Exclude C420-C424, C760-C768, C770-C779, C809

9650-9667

SEER Site Recodes for Mortality (ICD-10)

Site Description Site Codes

Oral cavity and pharynx Lip C00 Tongue C01-C02 Salivary gland C07-C08 Floor of mouth C04 Gum and other mouth C03, C05-C06 Nasopharynx C11 Tonsil C09 Oropharynx C10 Hypopharynx C12-C13Other oral cavity and pharynx C14

Digestive system Esophagus C15 Stomach C16 Small intestine C17 Colon C18, C26.0 Rectum C19-C20 Anus, anal canal, and anorectum C21 Liver C22.0, C22.2-C22.4, C22.7, C22.9 Intrahepatic bile duct C22.1 Gallbladder C23 Other biliary C24 Pancreas C25 Retroperitoneum C48.0 Peritoneum, omentum, and mesentery C45.1, C48.1-C48.2 Other digestive organs C26.8-C26.9, C48.8

Respiratory system Nose, nasal cavity, middle ear C30-C31 Larynx C32 Lung and bronchus C34 Pleura C38.4, C45.0 Trachea, mediastinum, and other respiratory organs C33, C38.1-C38.3, C38.8, C39

Bones and joints C40-C41

Soft tissue (including heart) C47, C49, C38.0, C45.2

Skin (excluding basal and squamous) Melanoma of the skin C43 Other, non-epithelial skin C44, C46

Breast C50

Female genital system Cervix C53 Uterine corpus C54 Uterus, NOS C55 Ovary C56 Vagina C52 Vulva C51 Other female genital organs C57-C58

Appendix 4

Appendix 4 (page 2)

SEER Site Recodes for Mortality (ICD-10)

Site Description Site Codes

Male genital organs Prostate C61 Testis C62 Penis C60 Other male genital organs C63

Urinary system Urinary bladder C67 Kidney and renal pelvis C64-C65 Ureter C66 Other urinary organs C68

Eye and orbit C69

Brain and other nervous system C70-C72

Endocrine system Thyroid C73 Other endocrine (including thymus) C37, C74-C75

Lymphoma Hodgkin lymphoma C81 Non-Hodgkin lymphoma C82-C85, C96.3

Myeloma C90.0, C90.2

Leukemia Lymphocytic Acute lymphocytic C91.0 Chronic lymphocytic C91.1 Other lymphocytic C91.2-C91.4, C91.7, C91.9 Myeloid and Monocytic Acute myeloid C92.0, C92.4-C92.5, C94.0, C94.2 Acute monocytic C93.0 Chronic myeloid C92.1 Other myeloid/monocytic C92.2-C92.3, C92.7, C92.9, C93.1-C93.2, C93.7, C93.9 Other leukemia Other acute C94.4-C94.5, C95.0 Aleukemic, subleukemic, and NOS C90.1, C91.5, C94.1, C94.3, C94.7, C95.1, C95.2, C95.7,

C95.9

Mesothelioma C45

Kaposi sarcoma C46

Ill-defined and unspecified sites C26.1, C45.7, C45.9, C76-C80, C88, C96.0-C96.2, C96.7, C96.9, C97

Source: http://seer.cancer.gov/csr/1975_2005/results_merged/topic_cod.pdf

Jefferson Acadia Avoyelles CaldwellOrleans Evangeline Catahoula East CarrollPlaquemines Iberia Concordia FranklinSt. Bernard Lafayette Grant Jackson

St. Landry La Salle LincolnSt. Martin Rapides MadisonVermilion Vernon Morehouse

Ascension Winn OuachitaEast Baton Rouge RichlandEast Feliciana TensasIberville Allen UnionPointe Coupee Beauregard Bienville West CarrollWest Baton Rouge Calcasieu BossierWest Feliciana Cameron Caddo

Jefferson Davis ClaiborneDe Soto LivingstonNatchitoches St. Helena

Assumption Red River St. TammanyLafourche Sabine TangipahoaSt. Charles Webster WashingtonSt. JamesSt. John the BaptistSt. MaryTerrebonne

Region 2

Region 3

Region 4

Region 5

Region 9

Appendix 5

Parishes in Louisiana Office of Public Health Regions

Region 6

Region 7

Region 8Region 1

Male Female Male Female Male Female Male Female Male Female

00‐04 years 810,352 776,616 460,138 439,251 332,500 320,463 5,745 5,229 11,969 11,67305‐09 years 804,507 771,489 461,065 438,039 325,618 316,560 5,682 5,377 12,142 11,51310‐14 years 860,611 821,314 492,415 466,231 349,143 337,283 6,490 6,272 12,563 11,52815‐19 years 874,165 858,002 513,611 496,578 340,211 342,958 7,082 6,584 13,261 11,88220‐24 years 873,363 868,277 535,994 519,136 314,833 329,075 6,291 6,036 16,245 14,03025‐29 years 724,845 734,447 466,819 449,016 237,021 266,036 4,970 5,022 16,035 14,37330‐34 years 707,822 738,650 473,760 470,059 213,843 249,562 5,091 4,496 15,128 14,53335‐39 years 752,219 790,170 508,923 504,521 224,491 267,412 5,002 5,207 13,803 13,03040‐44 years 822,676 868,715 566,656 566,936 238,669 283,807 5,407 5,624 11,944 12,34845‐49 years 803,809 844,785 557,515 555,082 229,944 272,073 4,972 5,251 11,378 12,37950‐54 years 707,989 753,617 500,467 507,169 193,666 231,304 4,462 4,224 9,394 10,92055‐59 years 566,470 615,117 416,288 433,864 139,511 169,779 3,584 3,526 7,087 7,94860‐64 years 429,486 488,028 322,500 350,778 99,492 129,560 2,570 2,657 4,924 5,03365‐69 years 339,401 404,368 256,729 291,747 77,467 107,041 1,815 1,733 3,390 3,84770‐74 years 278,523 364,834 216,062 272,037 58,827 88,490 1,276 1,350 2,358 2,95775‐79 years 217,229 318,327 171,843 242,966 43,171 72,434 808 1,076 1,407 1,85180‐84 years 136,035 235,246 107,629 183,221 27,126 50,398 495 620 785 1,00785+ years 92,187 222,610 68,807 169,450 22,423 51,621 373 711 584 828

Totals 10,801,689 11,474,612 7,097,221 7,356,081 3,467,956 3,885,856 72,115 70,995 164,397 161,680

Source: U.S. Census Bureau, Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, April 2008.

American

Indians/Alaska Natives

Asians or Pacific

IslandersTotals Whites Blacks

Appendix 6. Louisiana Population Counts, 2001‐2005 (five years)

Appendix 7

References

1. Percy C, Van Holten V, Muir C (eds). International Classification of Diseases for Oncology. 2nd edition. Geneva, Switzerland: World Health Organization, 1990. 2. Fritz A, Percy C, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (es). International Classification of Diseases for Oncology. 3rd edition. Geneva: World Health Organization, 2000. 3. Howe HL, Lake A, Firth R, Lehnherr M, Bayakly R, Copeland G, Wu XC, Stroup A, Roney D (eds). Cancer in North America, 2001−2005 (3 vols). Springfield, Ill.: North American Association of Central Cancer Registries, May 2008. Available in the Cancer Research section at: http://www.naaccr.org. 4. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds). Cancer Incidence in Five Continents, vol. 8. Lyon, France: International Association for Research on Cancer and International Association of Cancer Registries, 2002. (IARC Scientific Pub. No. 155.) 5. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2007. 6. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005. Bethesda, Md.: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/1975_2005 7. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (3 vols). Geneva, 1992. 8. North American Association of Central Cancer Registries. Age adjusting to the year 2000 standard. Available in the Education and Training Section, Training Modules Online, at: http://www.naaccr.org/index.asp?Col_SectionKey=10&Col_ContentID=64 . 9. American Cancer Society. Cancer Facts & Figures 2008. Atlanta, Ga.: American Cancer Society, 2008. Available at http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. 10. CDC and National Cancer Institute. State Cancer Profiles: http://statecancerprofiles.cancer.gov. 11. CDC Behavioral Risk Factor Surveillance System: http://www.cdc.gov/brfss/. .

Title page, Vol 23 - Public Healthsph.lsuhsc.edu › wp-content › uploads › 2016 › 08 › Vol23.pdfVolume 23 Cancer in Louisiana, 2001-2005 editors Patricia A. Andrews, MPH Meichin

Documents